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ABSTRACT  
Campylobacter jejuni is a major cause of gastroenteritis in humans. The capsule 
of some species contains unique modified heptoses. Heptose modification and novel 
epimerases and reductases were identified for C. jejuni NCTC11168 and 18-176. We 
hypothesized that heptose modifying enzymes in C. jejuni have specific catalytic residues 
that allow for substrate and product specificity. Substrate synthesis, structural modeling, 
point mutations, and enzymatic analysis have been applied to map the active sites. 
Putative catalytic residues showed substrate and/or product specificity. The epimerases 
structures were solved by crystallography done by our collaborator. We also 
hypothesized that synthesis of the modified heptoses is important for biofilm formation. 
In vitro experiment of C. jejuni NCTC11168 showed that the heptose modefication 
biosynthesis mutants have a significant reduction in biofilm formation under aerobic 
conditions.  
This project has provided essential information about the structure and 
mechanism of heptose modifying enzymes. It also will emphasize their importance in 
some C. jejuni virulence properties such as biofilm formation.  
 
Keywords: Campylobacter jejuni, Modified heptose, Epimerase, Reductase, Structure, 
binding site, Biofilm. 
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CHAPTER 1- INTRODUCTION 
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1.1. Campylobacter jejuni: 
1.1.1. History and taxonomy: 
In 1886, Theodor Escherich observed non-culturable spiral bacteria in a stool 
sample from a patient with diarrhea (48). Since then, the same organism has been 
frequently observed in bovines and ovines. Two decades after Escherich’s observation, 
McFaydean and Stockman were able to isolate vibrio-like bacteria from aborted bovines 
(113). In 1919, several investigations conducted by Smith and Taylor on bovines’ 
abortions in the USA led to the isolation of spiral bacteria. After confirming that these 
were the same as the vibrio-like bacteria isolated by McFaydean and Stockman, they 
proposed the name Vibrio fetus (155). In 1931, Johns et al isolated a dysentery related 
bacterium that they called Vibrio jejuni (52). The first human infection was reported in 
1938, from an outbreak of diarrhea caused by contaminated milk that affected 355 
individuals. V. jejuni was observed in most of the patients fecal samples (102). V. jejuni 
was then renamed as Campylobacter jejuni, derived from Greek word for the curved rod, 
in 1963 by Sebald and Ve´ron (153). 
1.1.2. General characteristics:  
C. jejuni is a spirally curved gram-negative bacteria 0.5 to 8 μm long and 0.2-0.5 
μm wide (101). It has rapid darting and spinning motion mediated by single polar or 
bipolar flagella. Biochemically, C. jejuni is catalase and oxidase positive, and urease 
negative. C. jejuni requires microaerobic conditions for growth, nitrogen-rich atmosphere 
with 5% oxygen and 10% carbon dioxide (101). As a source of energy, it utilizes amino 
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acids, which are considered the most important source of carbon, and tricarboxylic acid 
cycle intermediates (100, 127, 161). The best temperature range for growth is 34-44C, 
with an optimal temperature of 42C. Under stressful conditions, such as in cases of 
insufficient nutrition, temperature variation, or osmotic shock, C. jejuni tends to 
transform into coccoid form. Coccoids are a viable but not culturable form of bacterial 
cells that are metabolically active (132). The genome of C. jejuni is characterized by a 
circular chromosome of 1.6 megabases in size with 30.6% G+C content (135). 
 
1.2. Epidemiology and pathogenesis: 
Campylobacters have been recognized as an important cause of human enteritis. 
Among ten species, C. jejuni and C. coli were the cause of 95% of the enteritis cases, of 
which 90 % were caused by C. jejuni. It is a major bacterial cause of food-borne 
gastrointestinal infection, known as campylobacteriosis. C. jejuni is the third most 
common cause of diarrhea after E. coli and rotavirus in developing countries (5). 
Campylobacteriosis cases in developing countries are most common in children and 
immune-compromised individuals. In the developed world, C. jejuni infections are 
reported to be more frequent than Salmonella and Shigella infections combined (3). The 
incidence of campylobacteriosis has increased over the last ten years (81). According to 
the Centers for Disease Control and Prevention, 56 outbreaks of 1,550 illnesses were 
reported between 2009 and 2010 in the United States (65). In Canada, 49.69 
campylobacteriosis cases per 100,000 population were reported in the Waterloo region, 
Ontario, between 1990 and 2004 (85). The highest rate of campylobacteriosis incidence 
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within Canada was reported in the province of British Columbia with an annual average 
of  38 cases per 100, 000 population during 2005 and 2009 (81). 
C. jejuni is naturally found as a commensal in the lumen of poultry intestine, wild birds, 
and cattle. A high colonization level was found in the intestinal ceca of chickens, ranging 
between 105 to 109 colony forming units (CFU)/g (2, 22). Infections of humans with C. 
jejuni result from the consumption of undercooked poultry meat or cross-contamination 
with other food during food processing (59). The infection also can be acquired through 
the consumption of unpasteurized milk or contaminated water (28, 149).  
 
1.3. Clinical characteristics: 
1.3.1. Induced enteritis and immune response: 
C. jejuni infection induces acute inflammatory enteritis. The onset of 
campylobacteriosis symptoms starts one to three days following exposure to an 
infectious dose as low as 360-800 CFU (24). The symptoms start with abdominal pain, 
headache, dizziness, fever, and severe diarrhea. The patient starts having watery 
diarrhea, and as the disease progresses, it becomes bloody diarrhea (172). However, the 
infection is self-limiting, and it resolves within seven days. The severity of symptoms 
varies among different age groups. Infection in early childhood is more prevalent than in 
late childhood due to the development of immunity (24, 171, 187).  
The intestinal innate immune response plays an important role in fighting against 
C. jejuni through the production of cytokines and antimicrobial peptides (190). The 
humoral immune response against C. jejuni is important in humans (24, 25, 129). Fecal 
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IgA and plasma IgG C. jejuni specific antibodies response were reported (74, 98). The 
cellular immune response to C. jejuni is not well understood. C. jejuni can escape killing 
by human monocytes and survive intracellularly (68). An in vitro study showed the 
survival of C. jejuni 81-176 within vacuoles inside human 28SC monocytes (68). It also 
found that C. jejuni mediates apoptosis to the infected monocytes by activating the 
programmed cell death pathway (68). However in avian host cells, it was shown that C. 
jejuni cannot survive within chicken’s peritoneal macrophages in vitro (128). 
 
1.3.2. Immunological neuromuscular disorders:  
1.3.2.1. Guillain-Barre Syndrome (GBS): 
An autoimmune disease known as Guillain-Barre Syndrome is one of the long-
term consequences of C. jejuni infection, known as acute inflammatory demyelinating 
polyneuropathy. GBS is the most common cause of paralysis with yearly incidence up to 
1.7 per 100,000 population (6). Damage to the peripheral nerves is caused by infiltration 
of the immune cells and anti-gangliosides antibodies (33). It has been reported that up to 
60% of GBS cases have a history of bacterial infection 30 days before the onset of 
symptoms (64, 125). Many bacterial and viral infections can result in disease occurrence, 
such as C. jejuni, Mycoplasma pneumonia, and Epstein-Barr virus (56, 177). C. jejuni 
infection is the most common identified cause due to molecular mimicry on the 
lipopolysaccharide (LOS) (188). The LOS in some C. jejuni contains gangliosides mimic 
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structures, which induce the generation of antibodies that cross-react with the host 
gangliosides causing the disease. 
1.3.2.2. Miller Fisher syndrome (MFS): 
In contrast to GBS, Miller Fisher syndrome is a rare neurological disorder. It has 
mild clinical symptoms characterized by weakness of eye muscles and loss of full control 
of body movements (50). It also can be a consequence of earlier infections, such as 
influenza (66). The onset of MFS is often preceded by C. jejuni infection. A study 
containing 11 MFS diagnosed patients reported that 63 % of the patients have positive C. 
jejuni cultures (150). 
 
1.4. Virulence factors: 
1.4.1. Adhesion and invasion: 
In an avian host, C. jejuni colonizes the mucus layer and the crypts of the colon 
and the mucosa of the cecum. When humans are infected, the bacteria adhere to the ileum 
and colon to facilitate invasion. C. jejuni adhesion to the intestinal cells is essential for 
disease occurrence. Greater binding ability was observed in strains isolated from patients 
who experienced diarrhea and fever compared to the strains isolated from patients with 
no symptoms (49). C. jejuni expresses different adhesins, some of which have been 
studied extensively. An outer membrane protein, known as Campylobacter adherence 
factor (CadF), has been identified as an adhesin that binds to fibronectin on the 
extracellular matrix of INT-407 cells (90). According to in vivo and in vitro analysis, C. 
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jejuni lacking CadF are unable to adhere to or invade intestinal cells (122). Fibronectin 
binding is involved in the induction of signals that activate microfilaments 
polymerization for cell uptake, which suggests that CadF is also important for bacterial 
invasion (90). Another adhesin was identified, which is the surface lipoprotein JlpA. It is 
involved in C. jejuni adherence to HEp-2 cells (76). JlpA binding results in activation of 
the inflammatory response in the host (77). A periplasmic amino acid transporter, Ped1, 
was identified as an adhesin. Ped1mutants showed a decrease in adhesion and 
colonization to the cells (137). However, since Ped1 is localized in the periplasmic space 
of C. jejuni, the mechanism of its interaction with the host is still unknown.  
Intracellular C. jejuni have been observed in patients’ samples with diarrhea and 
in laboratory cell lines (41). C. jejuni cells need microtubule or microfilament 
polymerization for maximal invasion (23, 41). Internalization of C. jejuni is activated by 
the functional binding of CadF to fibronectin on the cell surface (90). Some secreted 
proteins required for C. jejuni invasion were identified, such as Campylobacter invasion 
antigen B (CiaB). The ciaB deficient strains are able to bind host cells, but are unable to 
invade them (92). Other virulence factors are found to play a role in C. jejuni adhesion 
and/or invasion to host cells including the flagella, Lipooligosaccharide (LOS), and the 
capsular polysaccharides (CPS) (18, 41). 
 
1.4.2. Intracellular survival: 
One of the most important C. jejuni virulence factors is the ability to survive in 
macrophages in a strain dependant manner. Different studies reported that C. jejuni 81-
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176, M129, 2964 strains can survive in human and/or murine macrophages for several 
days (43, 68, 86). On the other hand, NCTC11168 strain doesn’t survive beyond a few 
hours (184). Intracellular C. jejuni was found to induce proinflammatory responses in 
human monocytes. In addition, it was found to mediate cell arrest by the production of 
cytolethal distending toxin (CDT) and to induce apoptosis (68, 189). Infected human 
monocyte apoptosis was reported to be independent of CDT (154, 189). As reported from 
an in vitro experiment of M129 strain, C. jejuni survives in the intestinal cells and results 
in deterioration of the cell monolayers (91) . 
C. jejuni can also survive within free-living protozoa as a protective 
environmental host. Many studies reported the intracellular survival of C. jejuni in 
Acanthamoeba, which is a genus of amoeba commonly found in soil and water (29, 152, 
176). In fact, a longer survival period of C. jejuni was observed when C. jejuni cells were 
inside amoeba compared to being in culture media alone (15, 133). It was also found to 
survive at lower temperatures and to replicate inside the amoeba at 37C (14). On the 
other hand, studies showed that C. jejuni can only survive extracellularly (30, 44). The 
conflict in these findings could be explained by the different experimental techniques and 
different C. jejuni and Acanthamoeba strains used in different studies (176). 
 
1.4.3. Biofilm formation: 
C. jejuni cells can exist in biofilms to protect themselves and survive under 
unfavorable conditions. Biofilm formation protects the bacteria when they are out of the 
host, which allow their transition into another host or into food products during food 
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processing. The ability of C. jejuni to survive in the environment increases the chance of 
chicken colonization and food contamination, and thus human infection through 
consumption of this contaminated food. C. jejuni biofilms are found in water distribution 
systems and surfaces submerged in an aquatic environment (73). C. jejuni populations 
can exist in nature in different forms. They exist in biofilms, which are surface adherent 
bacterial populations enclosed by a matrix, known as extracellular polymeric substance 
(EPS) (38). The matrix composition is highly variable depending on the microbial species 
but it usually contains extracellular DNA, proteins, and polysaccharides (27). C. jejuni 
populations also can form aggregates that are not attached to a surface or pellicles at an 
air-liquid interface (80). Studies showed that C. jejuni can form a single species or mixed 
culture biofilms in the environment (73). Many factors can affect C. jejuni biofilm 
formation including a functional flagella, temperature, nutrition, or oxygen concentration 
(80, 145, 146). Strains with flagellar structure gene mutations showed a decrease in 
biofilm formation and inability to attach to surfaces (145). Other studies showed that 
aerobic conditions activate C. jejuni biofilm formation (146). Biofilm formation was 
proposed as a virulence factor because it provides protection for the bacterial cells from 
environmental stressors and from antibacterial agents (38). 
 
1.4.4. Flagella and motility: 
The polar flagella of C. jejuni have a critical role, not only in motility, but also in 
secretion, invasion, colonization, and biofilm formation (93, 107, 145). Motility is 
required for the bacteria to initiate infection in the host by penetrating the mucus layer in 
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the intestine (94). In vivo and in vitro experiments showed that non-flagellated C. jejuni 
are not motile and unable to invade cells (179). Equally important, the C. jejuni flagellar 
apparatus acts as a secretion system for virulence proteins, such as Cia proteins that are 
important for adhesion (93). 
 More than 40 genes participate in the formation and regulation of the flagellar 
structure, which consists of a basal body, hook, and a hollow cylindrical filament. The 
building units of the flagella are two structural proteins FlaA and FlaB. Both are 
regulated by FlgS/FlgR, a two component system, and sigma factors (σ28, σ54) (67, 105, 
185). Transposon mutagenesis experiment found that σ28 and σ54 regulate the 
production of FlaA and FlaB respectively. Based on in vitro study of flaA-flaB+ mutants, 
expression of FlaA was found to be more significant for motility and invasion of 
intestinal cells than FlaB (61). C. jejuni flagellin is heavily glycosylated. This 
glycosylation is known to occour through an O-linked glycosylation system. O-linked 
glycosylation is important for flagellar filament assembly and motility (62). 
 
1.4.5. Glycosylation: 
Protein glycosylation is an essential biological process in all life domains where a 
particular protein is modified by the addition of sugar structures. Glycosylated proteins 
are essential for multiple cellular functions (121). Bacterial protein glycosylation was 
discovered in many organisms after it was thought to exist only in eukaryotes (169). 
Many prokaryotes have been found to modify proteins by adding sugars either through 
the hydroxyl groups of serine and threonine residues (O-linked), or the amide group of an 
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asparagine residue (N- linked) (121). O-linked glycosylation was observed in the pilin 
subunit of Neisseria meningitides, the surface layer proteins of Colstridium symiosum and 
Streptococcus sanguis as well as in the flagellin of Pseudomonas aeruginosa (26, 119, 
120) C. jejuni encodes two glycosylation loci for both glycosylation types, which makes 
it an effective model to study bacterial protein glycosylation by constructing knockout 
mutants (166). The O-linked glycosylation locus is extremely variable among different 
strains of Campylobacter species. C. jejuni flagellin proteins are of the most heavily O-
glycosylated bacterial proteins. O-linked glycosylation plays an essential role in the 
flagellin assembly and thus the motility of C. jejuni cells (62). The location of the O-
linked glycans as exposed moieties on the flagellin indicates a significant potential for 
interaction with the host cells. Studies showed that O-linked glycosylation is important 
for adhesion, and invasion of the host cells (62). Unlike the O-linked glycosylation loci, 
N-linked glycosylation loci is highly conserved among C. jejuni strains and has no 
putative phase-variable genes (168). Disruption of the N-linked glycosylation pathway in 
C. jejuni significantly reduces adhesion, invasion and colonization of chickens (78, 165). 
 
1.4.6. Lipooligosaccharide (LOS): 
The lipooligosaccharide (LOS) and lipopolysaccharide (LPS) are important 
virulence factors found in the outer membrane of mucosal gram-negative bacteria (140). 
LPS are high molecular weight (High Mr) glyco-lipids composed of oligosaccharide core 
attached to lipid A, in addition to surface-exposed repeating units of polysaccharide, O-
antigen. On the other hand, LOS are low molecular weight (low Mr) with the same main 
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structure of LPS, except that it lacks the O-antigen. Two decades ago, C. jejuni was 
considered to contain both LPS and LOS (141). The discovery of the capsular gene 
cluster proved that C. jejuni’s high molecular weight polysaccharide is in fact capsule 
(84, 135). C. jejuni LOS structure has been extensively studied. Lipid A, the hydrophobic 
membrane anchor, has a conserved structure among Gram-ngative bacteria. It consists of 
two phosphorylated D-glucosamines in (1-6) linkage and attached acyl chains (104, 126, 
142). The oligosaccharide chain has been divided into inner and outer core, based on the 
different sugar composition. The inner core  structure is conserved among various strains, 
containing a backbone of 2-keto-3-deoxyoctulosonic acid (Kdo), two L-glycero-D-
manno-heptoses (L, D-Hep), D-galactose (D-Gal), and terminal D-glucose (D-Glc) (123, 
160). The outer core is structurally diverse among C. jejuni strains. To date, the structure 
of more than ten C. jejuni serostrains LOS outer core have been identified (10-12, 58, 
160, 167). LOS is an important structure for bacterial transition across the intestinal 
epithelial cells, and for immune evasion (106, 109).  A remarkable feature in the C. jejuni 
LOS is that it possesses structures that mimic humans’ peripheral nerves gangliosides. 
This mimicry contributes to autoimmune neurological disorders upon infection, such as 
GBS and MFS (57, 58, 72, 124, 125).  
1.4.7. Capsule polysaccharide (CPS): 
Like many other Gram-negative bacteria, C. jejuni possesses capsular 
polysaccharide surface structure. The capsular polysaccharide (CPS) is made of high 
molecular weight polysaccharides, organized in repeated units of carbohydrates called K-
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antigen. This K-antigen is attached to the outer membrane by a phospholipid anchor. CPS 
structures are extremely diverse, not only between different species but also between 
different strains within the same species (82). The highly diverse structure makes them a 
major component of the classical Penner serotyping system (84). The variation is 
attributed to different genetic components and extensive phase variable modifications in 
favor of evading the host immune response (148).  
C. jejuni CPS acquire unique modifications as different strains express heptoses 
of unusual configuration such as, D-altro-, L-gluco-, ido- heptoses (9, 111, 160). Further 
heptoses modifications can be acquired in C. jejuni CPS by C6 dehydration to generate 6-
deoxy-heptose found in 81-176 strain (110). In addition, an O-methyl phosphoramidate 
group (MeOPN), which is a rare labile phosphorylated structure, is found attached to the 
modified heptose and to different sugar components in multiple strains (114-116).  
The K-antigen backbone structures of different C. jejuni strains have been 
identified. C. jejuni 81-176 contains repeated units of β-D-N-acetylglucosamine (β-D-
GlcNAc), α-D-galactose (α-D-Gal), and the modified heptose 6-deoxy-D-altro-heptose. 
On the other hand, C. jejuni NCTC 11168 CPS backbone contains repeated units of β-D-
Ribofuranose (D-Ribƒ), β-D-2-acetamido-2-deoxy-β-D-galactofuranose (β-D-GalƒNAc), 
-D-glucuronic acid (α-D-GlcpA) with 2-amino-2-deoxyglycerol (GroN), and a modified 
heptose 3,6-OMe-L-gluco-heptose (9, 160). 
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Figure 1: Schematic representation comparing the CPS structure and the modified 
heptoses of C. jejuni 81-176 and NCTC 11168. A. the CPS of C. jejuni 81-176 contains 
phospholipid anchor (PL) and attached repeated units of  D-GlcNAc (1), D-Gal (2), and 
the modified heptose 6-deoxy-D-altro-heptose (H1), represented in chemical structure 
underneath. B. the CPS of C. jejuni NCTC 11168 contains repeated units of D-Ribƒ (1), 
D-GalƒNAc (2), D-GlcpA (3), and a side branch  of modified heptose 3,6-O-Me-L-gluco-
heptose (H2), represented in chemical structure underneath. 
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1.4.7.1. CPS genetics: 
CPS has been recently classified in E. coli into four groups based on genetic and 
synthetic properties (181). C. jejuni CPS resemble both group II and III enterobacterial 
capsules. Both groups corresponding gene clusters are characterized by two conserved 
regions containing genes involved in assembly and transport (region 1, 3), flanking a 
major biosynthetic region (region 2) (Figure 2). Region 2 is the strain-specific region that  
includes genes encoding the various sugar nucleotide synthetases for the K-antigen (148). 
In group III CPS, four conserved genes belong to region 1, kpsE, kpsT, kpsM, and kpsD. 
While in C. jejuni there is a fifth gene, kpsF, which could have a regulatory role in the 
export of the capsule chain (35, 36). KpsE and KpsD play a role in the translocation of 
the polysaccharide chain across the periplasmic space to the outer membrane (8). While 
KpsM and KpsT are ABC-transporters involved in transporting the polysaccharide across 
the inner membrane to the periplasmic area (131, 139). Region 3 contains two genes, 
kpsS and kpsC (84). Homologues kpsS and kpsC genes in group II CPS in E. coli are 
involved in attaching the Kdo, which is synthesized by KpsU, to the phosphatidic acid 
and subsequently to the polysaccharide’s reducing end (183). However, the lack of kpsU 
in C. jejuni suggests that the K-antigen is not linked to the phospholipid via Kdo. 
Therefore, kpsS and kpsC could be encoding proteins that are involved in attaching the 
polysaccharide into the phospholipid anchor. 
 In C. jejuni NCTC 11168, the capsular genes cluster was identified in 2000 by a 
complete genome sequencing (83, 84). After this discovery, several studies were 
dedicated to investigate the function of the genes in CPS biosynthesis and structural 
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diversity. The biosynthetic region (region 2) of six C. jejuni strains was studied and 
compared to the sequenced strain NCTC 11168 (82). The study revealed that the 
structural diversity is related to variation in region 2 of the capsular cluster. Despite the 
variations, several genes involved in particular sugar synthesis or modifications were 
conserved between several strains, including the heptose synthesis genes, cjj1423c 
(hddC), cjj1424c (gmhA2), and cjj1425c (hddA). Genes involved in heptose 
modifications were identified in C. jejuni 81-176, cjj1425 (wcaG), cjj1426 (ddahA), 
cjj1427 (ddahC), and cjj1430 (ddahB), as well as in NCTC 11168 strain cj1426, cj1427 
(wcaG), cj1428 (mlghC), and cj1430 (mlghB) (82, 111). MeOPN synthesis genes 
(cj1415c - cj1418c), and two genes (cj1421c and cj1422c) encode transferases for the 
addition of MeOPN to D-GalƒNAc and D-α-L-glucoHepp, respectively. In addition, 
cj1426c (mlghD) is reported to methylate the 3,6-O-Me-L-gluco-heptose at O6, while 
cj1419c could be responsible for the methylation at O3 (Creuzenet lab, unpublished) 
(111, 164) (Figure 3). 
 
1.4.7.2. CPS synthesis: 
The synthesis of the capsule has been extensively studied in E. coli for the three 
groups. Since C. jejuni capsule resembles group II and III, the synthesis mechanism of 
these groups only will be explained in this section (Figure 2). CPS synthesis starts in the 
cytoplasm where the phosphosugar nucleotide precursors are polymerized prior to being 
exported to the periplasmic space. There, specific surface translocation reactions take 
place to export CPS to the cell surface (162).  
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While the initiation mechanism of the polysaccharide synthesis remain unknown, 
the synthesis process has been shown to take place on the cytoplasmic face of the plasma 
membrane (181). A membrane-bound complex, consisting of glycosyltransferases (KfiA-
D) and Kps proteins,  is believed to be the origin of the synthesis process (147). The 
elongation of the polysaccharide chain is carried out by the glycosyltransferases at the 
non-reducing end in a sequential pattern. The growing polysaccharide chain is then 
transported across the inner membrane to the periplasmic space. The Kdo attachment to 
the reducing end of the polysaccharide in group II CPS is believed to occur before the 
export step. This fact was concluded from the accumulation of the polysaccharides 
lacking Kdo in the cytoplasm due to mutations in KpsC and KpsS (148). However in 
group III and C. jejuni CPS where there is no Kdo, it is believed that KpsC and KpsS are 
involved in attaching the polysaccharide chain to the phospholipid (84). The translocation 
of the capsule to the cell surface occurs through periplasmic scaffolds. These scaffolds 
are areas where the cell plasma membrane and the outer membrane are in proximity 
forming structures called Bayer junctions (182). The ABC transporter, KpsM and KpsT, 
form a functional transporter dimer that binds directly to the polysaccharide and exports 
it through an export channel. KpsD, which is a transporter protein in the periplasmic 
space, could be involved in joining the membranes closely to facilitate the export to the 
outer membrane (8).  
The regulation of CPS expression in C. jejuni is not fully understood. There is no 
experimental evidence of transcriptional regulatory patterns in CPS gene cluster. 
However, some findings suggest that some genes are regulated differently depending on 
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the growth conditions. High iron growth conditions are found to up-regulate the 
expression of four genes in region 2 in C. jejuni NCTC 11168 (134). Furthermore, down-
regulation of three biosynthesis genes and four transport genes was reported after serial 
passage of C. jejuni NCTC 11168 or 81-176 with HCT-8 human intestinal cells (37). 
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Figure 2: Schematic representation of CPS cluster regions. E. coli group II and III 
CPS regions compared to C. jejuni NCTC 11168 CPS cluster. 
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Figure 3: Schematic representation of region 2 of both C. jejuni NCTC 11168 and 
81-176 strains. The genes involved in GDP-manno-heptose synthesis and modification, 
as well as the phosphoramidate synthesis and transfer genes.
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1.4.7.3. Biological role in virulence: 
CPSs are an essential part of the bacterial cell as they are involved in many 
different functions. They provide protection from environmental conditions and host 
defenses. Most importantly, they play an important role in bacterial pathogenesis and 
virulence (170). The involvement of the capsule in C. jejuni virulence is strain dependant.  
Multiple studies conducted on different strains of a capsule less mutant (KpsM) 
revealed different results. In C. jejuni 81-176 strain, the KpsM mutant showed inability to 
colonize or to invade cells. In a ferret model, as well as in intestinal cells, the KpsM 
mutant of C. jejuni 81-176 strain exhibits decreased invasion levels (18, 109). However 
in NCTC 11186 strain, although the KpsM mutants showed a significant reduction in the 
colonization of chicken intestine, it was more adhesive and invasive to the epithelial cells 
in vitro than the wild type (78, 184).  
 CPS also protects C. jejuni from the innate immune system mediators, such as 
serum complements, and cationic antimicrobial peptides (109). Indeed, KpsM mutant in 
NCTC 11186 strain showed high susceptibility to serum, bile salt and phagocytosis (184). 
It is also believed that the extensive structural variation of CPS within C. jejuni strains 
protects the bacteria from bacteriophages and helps in evading the host immune response 
(71, 84). However, the complete mechanisms of these phase variable modifications in 
virulence still unknown.  
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1.5. GDP-manno-heptose synthesis: 
Heptose sugar is a natural component of the LOS and LPS of most Gram-negative 
bacteria. They are producing ADP-L-glycero-D-manno-heptose as a component of the 
core oligosaccharide by a single synthesis pathway (88, 95, 175). Interestingly, some 
strains of C. jejuni possess additional heptose biosynthesis pathway to produce GDP-D-
glycero-α-D-manno-heptose (GDP-manno-heptose). An identical pathway was identified 
in Aneurinibacillus thermoaerophilus and the enzymes have been used for an in vitro 
synthesis of GDP-manno-heptose for biochemical analyses (31, 87) (Figure 4). The genes 
involved in the synthesis of GDP-manno-heptose in C. jejuni are encoded in region 2 of 
the capsular cluster (Figure 3). The synthesis pathway starts by the conversion of D-
sedoheptulose-7-phosphate (sedoheptulose-7P) into D-glycero-α-D-manno-heptose-7-
phosphate (heptose-7P) by the phosphosugar isomerases GmhA. The kinase HddA then 
adds a phosphate group to generate D-glycero-α-D-manno-heptose-1,7-biphosphate 
(heptose-1,7P). One phosphate is removed by GmhB giving D-glycero-α-D-manno-
heptose-1-phosphate. Lastly, HddC acts to add a guanine nucleotide from a Guanine 
triphosphate molecule (GTP) to generate the activated end product GDP-D-glycero-α-D-
manno-heptose (82, 175). In some C. jejuni strains, this heptose is further modified 
before integration into the CPS.   
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Figure 4: Synthesis of GDP-D-glycero-D-manno-heptose.  The biosynthesis enzymes 
of GDP-D-glycero-D-manno-heptose in C. jejuni are in bold to the left of the reaction 
arrows, and the synthesis enzymes in Aneurinibacillus thermoaerophilus are to the right 
side of the arrows.
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1.6. C. jejuni GDP-manno-heptose modification: 
Unique configurations of heptose are expressed in the CPS of different pathogenic 
bacteria, in C. coli, and in Burkholderia pseudomallei (9, 10, 144, 160). They are also 
found in molecules other than the CPS such as in the exopolysaccharide of C. lari and the 
lipopolysaccharide of Yersinia pseudotuberculosis (13, 151). These modified heptoses 
are important for bacterial virulence and could be involved in bacteria-host interaction. 
In C. jejuni 81-176 and NCTC 11168 strains, two modified heptoses were 
identified, 6-deoxy-D-altro-heptose and 3,6-OMe-L-gluco-heptose, respectively (9, 160). 
The genes involved in the synthesis of the modified heptoses, as well as their synthesis 
pathways, have been characterized (110-112). 
1.6.1. The modified heptose role in virulence: 
Complex carbohydrates are usually found on the bacterial cell surface and they 
are involved in virulence or immune evasion. They are essential components of the CPS 
and LOS in pathogenic bacteria. Enzymes involved in the biosynthesis and modification 
of these sugars have gained much attention as antibacterial targets due to their 
involvement in virulence. For example, a well-studied C3/C5 epimerase (RmlC) and 
other homologous enzymes, in E. coli, Pseudomonas aeruginosa, Streptococcus mutants, 
and Mycobacterium tuberculosis, are involved in the dTDP-L-rhamnose synthesis 
pathway (143, 163). Deletion of one of the genes involved in this pathway resulted in a 
significant decrease in virulence (143, 173). Likewise, a C3/C5 Epimerase/C4 reductase 
(GFS) is involved in the GDP-L-fucose synthesis pathway. L-fucose is essential for 
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virulence and host mimicry of some pathogenic bacteria, such as E. coli and H. pylori 
(124, 157).  
All these examples are for hexose derivatives made by hexose-modifying 
enzymes. The enzymes that are involved in the synthesis of heptose derivatives are also 
found to play a key role in the virulence of many pathogens, such as Yersinia 
pseudotuberculosis, E. coli, and C. jejuni (70, 175, 184). In Y. pseudotuberculosis, 
disrupting the synthesis of these modified heptoses has been shown to decrease virulence. 
Mutants lacking the 6-deoxyheptose in the LPS are less motile and more sensitive to 
antimicrobial peptides (70). Recently, the involvement of the modified heptoses in the 
virulence of C. jejuni NCTC 11168 has been elucidated in vitro by testing four heptose 
biosynthesis mutants, wcaG::cat, mlghB::cat, mlghC::cat, and wcaG∆::cat (Figure 5) 
(184). In the serum and bile salt killing assay, all mutants were more susceptible to 
killing than the wild type, with different survival ratio for each. In the epithelial cells 
adhesion and invasion assay, mlghB::cat and mlghC::cat were not invasive to epithelial 
cells (130, 184). In addition, all mutants showed less colonization in the chicken intestine 
compared to the wild-type with variation between the mutants (184). All these data 
indicate the role that the modified heptoses have with respect to bacterial colonization, 
invasion of host cells, and response to host defense. 
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Figure 5: Schematic representation of region 2 of C. jejuni NCTC 11168 heptose 
biosynthesis mutants and the capsule-less mutant. From top to bottom, showing the 
deletion positions in each of wcaG::cat, mlghC::cat, mlghB::cat,  wcaGΔ::cat, and 
kpsM::kan strains (184). 
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1.6.2. The modified heptose synthesis enzymes: 
Several nucleotides modifying enzymes are encoded in region 2 of C. jejuni 81-
176 and NCTC 11168 CPS cluster. The 6-deoxy-D-altro-heptose synthesis enzymes in C. 
jejuni 81-176 are DdahA, DdahB, and DdahC, a C4/C6-dehydratase, C3-epimerase, and a 
C4 reductase, respectively. A post-transcriptional regulatory enzyme, WcaG, is a C4 
reductase. On the other hand, the enzymes involved in the 3,6-OMe-L-gluco-heptose 
synthesis in C. jejuni NCTC 11168 strain are MlghB and MlghC, encode a C3/C5 
epimerase and C4 reductase, respectively. A homologue to WcaG has also been identified 
(110-112). In addition, two methyltransferases were identified. The O6 methyltransferase 
is Cj1426, and it was renamed MlghD following the alphabetical order of the synthesis 
enzymes in the pathway. Preliminary data from Creuzenet lab showed the O3 
methyltransferase could be Cj1419, renamed as MlghE (unpublished).  
 
1.6.3. The modified heptose synthesis pathways: 
The homologous epimerases, DdahB and MlghB, are 81% identical and 98% 
similar in their protein sequence. While the homologous reductases, DdahC and MlghC, 
are 57% identical and 90% similar. Despite this similarity, these enzymes perform a 
strain-specific activity to generate strain-specific modified heptoses.  
The synthesis pathway for GDP-6-deoxy-D-altro-heptose in C. jejuni 81-176 was 
first established in our laboratory by the characterization of the first enzyme in the 
pathway, DdahA, and the regulatory enzyme WcaG (110, 112). DdahA performs 
sequential dehydration activity on C6 and C4 of the substrate GDP-manno-heptose to 
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generate GDP-6-deoxy-4-keto-D-lyxo-heptose (P1). This product can be either reduced at 
C4 by WcaG, with the co-factor NADPH, in a side-branch pathway to down-regulate the 
end product formation, or epimerized in a linear pathway to produce the final product. In 
the linear pathway, DdahB epimerizes P1 on C3 to produce GDP-6-deoxy-4-keto-D-
arabino-heptose. This product is then reduced at C4 by DdahC, with the co-factor 
NADPH, to yield the final product GDP-6-deoxy-D-altro-heptose (Figure 6-A). 
In NCTC 11168 strain, the 4-keto derivative of the GDP-manno-heptose is 
predicted to be generated by C4 oxidation activity. This oxidation is necessary to 
generate the substrate for the epimerase MlghB. However, no gene coding C4-oxidases 
was identified in the heptose modifying genes area or anywhere in the genome.  In vivo, 
MlghB generates GDP-4-keto-L-xylo-heptose from the oxidized substrate. This product is 
reduced at C4 by MlghC to give the final modified heptose GDP-L-gluco-heptose that is 
O-methylated at O6 and O3 by MlghD and MlghE, respectively (Figure 6-B). However, 
the location of the methylation events in the pathway is still under investigation.  
Because the potential GDP-manno-heptose oxidase has not been identified, 
MlghB’s substrate is not available for biochemical studies. The GDP-6-deoxy-4-keto-D-
lyxo-heptose (P1) generated by DdahA was used as a surrogate substrate for MlghB in an 
experimental pathway (Figure 7). MlghB performs C3, C5, or both epimerizing activity 
on P1 to generate three products in equilibrium, GDP-6-deoxy-4-keto-L-arabino-heptose 
(P4α), GDP-6-deoxy-4-keto-L-ribo-heptose (P4β), and GDP-6-deoxy-4-keto-L-xylo-
heptose (P4γ). An interconversion between P1 and the three epimerized products was 
observed.  Finally, P4γ is reduced by MlghC at C4 to produce the final modified heptose 
29 
 
 
 
GDP-6-deoxy- L-gluco-heptose (P5γ). The C3 epimerized product (P4α) generated by 
MlghB from the surrogate substrate was identical to the DdahB product. This observation 
was supported by the fact that the DdahC can also use P4α obtained by MlghB to 
generate GDP-6-deoxy-D-altro-heptose (P5α). 
The existence of strain-specific features of these enzymes suggests the importance 
of understanding the molecular structure and the mechanism of performing such specific 
activity. No structure for these enzymes or for homologous GDP-manno-heptose 
modifying enzymes was available at the onset of our studies. 
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Figure 6: Comparative GDP-6-deoxy-D-altro-heptose and GDP-3,6-O-Me-L-gluco-
heptose in vivo synthesis pathways of C. jejuni. A. The established synthesis pathway 
of GDP-6-deoxy-D-altro-heptose in 81-176 strain. B. The investigated synthesis pathway 
of GDP-3,6-O-Me-L-gluco-heptose in NCTC 11168 strain. MlghA is an oxidase 
(unknown). MlghD and MlghE are the methyl transferase that introduces methyl group to 
O6 and O3, respectively in yet unidentified locations along the pathway. Possible 
methylation sites are denoted by a question mark. Reproduced figure from (McCallum, 
2013) (111). 
  
  
 
Figure 7: Experimental pathway for GDP-6-deoxy-D-altro-heptose and GDP-6-
deoxy- L-gluco-heptose synthesis in vitro. MlghB generates P4α, P4β and P4γ from the 
surrogate substrate P1 that is formed by dehydration of GDP-manno-heptose by DdahA. 
MlghC reduces P4γ to form the final product GDP-6-deoxy- L-gluco-heptose. While 
DdahC reduces P4α to give for GDP-6-deoxy-D-altro-heptose. Reproduced figure from 
(McCallum, 2013) (111). 
32 
 
 
 
1.7. Enzymes structure: 
To study the configuration of an enzyme binding site, it is crucial to solve the 
three-dimensional structure. The 3D structure will provide essential biological and 
biochemical data that cannot be provided by a linear amino acid sequence. The tertiary 
structure can be obtained by a well-established experimental methods such as X-ray 
crystallography and nuclear magnetic resonance (NMR) (97). There are also 
computational methods dedicated to determine the structure in silico, known as protein 
structure modeling. 
1.7.1. Homology modeling: 
Homology modeling, also known as template-based modeling (TBM), refers to 
the prediction of the 3D structure of a protein based on its homology with a protein of 
experimentally determined structure (186). Four decades have been spent on establishing 
and developing ways to solve proteins structures by computational scientists (108). 
Homology modeling is an important and feasible method to solve the structure of  
proteins that cannot be solved experimentally due to the limitations and the difficulties of 
the experimental approaches (1, 108, 186). 
There are four main steps for homology modeling (96, 186). The primary 
sequence of the protein is needed first to identify homologous proteins through the 
protein data bank (PDB). Second, the sequence is aligned to the template sequence using 
one of the different reliable alignment softwares. Sequence alignment is the most 
important step in homology modeling, and any error in this step is irreversible (186). 
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Based on the alignment between the protein and the template, the model building can be 
achieved by the generation of the backbone and modeling the structural loops and side-
chains (96). Then comes to the last step, which is the model refinement and optimization. 
In this step, the side-chains are tuned by predicting the side-chain rotamers with high 
accuracy based on different parameters (96, 186) 
There are many software that are widely used for model building available for 
public, such as NEST, COMPOSER, SWISS-MODEL, and MODELLER (186). SWISS-
MODEL is a web-based workspace that uses a structure template database derived from 
the Protein Data Bank (7). The closest homology of the template to the target is identified 
using BLAST query. The templates with the highest quality are selected for model 
building (7). Model quality estimation is done using the Qualitative Model Energy 
Analysis (QMEAN) scoring system. It is a scoring system that describes the major 
geometrical conditions of protein structures (20).  
1.7.2. X-ray crystallography: 
X-ray crystallography is one of the most advanced techniques to investigate the 
molecular structure of a protein. X-rays are high-energy electromagnetic waves with a 
very short wavelength. Crystallographers use x-rays that range from 0.5 to 1.5 angstrom 
as rulers to measure the distance between atoms in a crystal (156).  In crystalline solids, 
the interatomic spacing is used as a diffraction gradient for x-rays with a wavelength of 
approximately one angstrom.  
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There are three main steps for protein crystallography analysis (117). Taking into 
account the fact that each step has its limitation, the whole technique can be time 
consuming and may not be successful with all proteins (1, 42). The first step is protein 
crystallization. The principle of crystallization is to obtain the protein in a solid form out 
of the solution in a fixed biological conformation. The protein crystals are grown by 
precipitation and condensation (156). The second step is firing a beam of x-rays at the 
tiny crystal of the studied protein. The crystal scatters the x-ray into specific diffraction 
patterns that are photographed by an electronic detector. Different orientations of the 
crystal are needed to capture in three dimensions different diffraction patterns of the x-
ray. These patterns are used to mathematically solve the precise position and arrangement 
of atoms in the crystal using Bragg’s law (75). The last step is data processing and 
analysis (159). Although it is a mathematically complex procedure, there are well-
established softwares to process the data (136, 159, 174). After several stages of analysis 
and troubleshooting, comes the refinement to produce a three-dimensional digital image 
of the protein. 
1.8. Enzymes active site: 
Enzymes are one of the most studied biological molecules because they catalyze 
numerous reactions in nature. The functional portion contains a combination of residues 
side chains that form the catalytic unit (191). This unit is also known as the catalytic 
toolkit. In this catalytic toolkit, the polar and charged amino acids are generally involved 
directly in catalysis (63). Hydrophobic residues are also observed in the active site of the 
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enzymes. Although the hydrophobic residues are not involved directly utilizing reactions, 
they do have an important roles in some enzymes, such as providing a proper medium 
environment in the active site (63). Catalytic residues are defined by Zvelebil. et. al as the 
amino acids that are directly involved in the catalysis by acting as general acid-base, 
electrophiles, or nucleophiles (191). They also can be involved in polarizing or stabilizing 
transition state intermediates. Bartlett. et. al added that residues that have an effect on 
other residues or water molecules that are directly involved in catalysis should also be 
classified as catalytic (19). Other group proposed that catalytic residues cloud have a 
secondary interaction with other residues, which were classified as non-catalytic, to aid 
the catalysis (63). This means that catalytic residues do not function independently. The 
microenvironment provided by other residues in the active site is important for the 
catalytic residues to function. 
One of the catalytic residues that are most often found in enzymes active sites is 
histidine. Histidine has a pKα close to neutral, which allows it to function as an acid-base 
catalyst. It can also donate or accept hydrogen atom, stabilizes charged transition states, 
and function as a nucleophile. Glutamate, aspartate, arginine and lysine are also 
commonly found in active sites. These residues can provide charges that exert an effect 
on other residues or on the substrate. Serine, threonine, tyrosine, glutamine and 
asparagine are found less often. These residues need to be activated by interacting with 
other residues to function. 
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1.9. Rational and hypothesis: 
The existence of modified bacterial surface carbohydrates and their involvement 
in bacterial virulence urge to further investigate their contribution to the pathogenesis in 
details. The identification of these modified carbohydrate synthesis genes shed light on 
important sugar-nucleotide modifying enzymes including dehydratases, epimerases and 
reductases. Several studies showed that deletion of one of the  sugar-nucleotide 
modifying enzymes encoding genes results in interruption of the pathway and 
consequently reduces the virulence of the organism (70, 143, 173, 175, 184) . These 
findings suggest that theses enzymes could be potential antimicrobial targets. In fact, 
successful attempts were made to design inhibitors for different enzymes, such as RmlC 
in M. tuberculosis, and the first two enzymes in the GDP-manno-heptose synthesis 
pathway (16, 47).  
In C. jejuni, heptose epimerases and reductases were identified in two strains, 81-
167 and NCTC 11168. These enzymes are highly similar yet perform strain-specific 
activities to generate different modified heptoses. They possess an interesting substrate 
and products specificity, which warrants an investigation of their binding sites. However, 
no structure of these enzymes or of homologous GDP-manno-heptose modifying 
enzymes is available. Therefore, we hypothesized that the heptose modifying enzymes 
in C. jejuni have specific catalytic residues that allow for substrate and product 
specificity toward heptose-based substrate rather than hexose-based substrate. 
These catalytic residues allow the enzymes to function differently on heptose despite 
the high sequence and structure similarity. 
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The role of the modified heptoses has been investigated with regards to bacterial 
resistance to serum and bile salt, adhesion and invasion to host cells, as well as 
colonization of the chicken reservoir of C. jejuni. However, their role in biofilm 
formation, which is one of the virulence factors that allows bacterial persistence in 
nature, still needs to be investigated. For this, we hypothesized that synthesis of the 
modified heptoses is important for biofilm formation. 
1.10. Objectives: 
First, to investigate the structure and the active site of the epimerases (DdahB and 
MlghB) and the reductases (DdahC and MlghC), enzymatic and structural approaches 
were employed. All enzymes were structurally modeled on well-studied hexose-
modifying enzymes homologues. The molecular structures of the enzymes were solved 
by X-ray crystallography, done by a collaborator (Laura Woodward, under supervision of 
Dr. James Naismith, St, Andrews University, UK). The starting substrate, GDP-manno-
heptose, was synthesized in the lab for structural and enzymatic analysis. We also applied 
site-directed mutagenesis to test specifically targeted residues for their involvement in 
catalysis or substrate specificity. The enzymatic activity, product formation, and kinetics 
were analyzed by capillary electrophoresis. 
  Second, to study biofilm formation, an in vitro biofilm formation experiment was 
performed on the wild type C. jejuni NCTC11168 and on five capsular and heptose 
biosynthesis mutants, kpsM, mlghB::cat, mlghC::cat, wcaG::cat, and wcaGΔ::cat. 
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CHAPTER 2 – MATERIAL AND METHODS
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2.1. Bacterial growth and culture conditions: 
Escherichia coli strains, DH5α, ER2566, and BL21(DE3)pLysS were routinely 
grown from -80C freezer stocks at 37°C on Luria Broth (LB) media (Bioshop, Canada). 
They were grown either on agar plates or in broth shaking at 200 rpm. Antibiotic 
supplements were added based on specific selection used at final concentration of 100 
μg/ml ampicillin (Biobasic, Markham, Canada), 100 μg/ml carbenicillin, 30 μg/ml 
kanamycin (Biobasic, Markham, Canada), and 34 μg/ml chloramphenicol (Fisher 
Scientific, Canada). C. jejuni ATCC 700819 ( NCTC 11168), wild type and mutant 
strains, were grown initially from -80C freezer stocks overnight on Tryptic Soy Agar 
(TSA; BD, Canada). The media was supplemented with 10 μg/ml vancomycin (Biobasic, 
Markham, Canada), 5 μg/ml trimethoprim (Sigma-Aldrich, Canada), and 5% sheep blood 
(Cedarlane, Burlington, Canada). Either 15 μg/ml chloramphenicol or 90 μg/ml 
kanamycin was added for selection of the mutants. C. jejuni cells were grown in a 
microaerobic incubator (Nuaire) at 37°C in 5% oxygen, 10% carbon dioxide, 85% 
nitrogen, and 90% humidity. Cells were then transferred onto another TSA plate and 
grown for 24 hours. To grow C. jejuni in liquid media, Tryptic Soy Broth (TSA; BD, 
Canada) was used. Media was supplemented with vancomycin, trimethoprim, 0.05% 
pyruvate (Alfa Aesar, USA), and 5% horse serum (Invitrogen, Canada) and grown 
shaking at 90 rpm. 
40 
 
 
 
2.2. Calcium chloride competent E. coli preparations: 
To prepare competent E. coli DH5α, ER2566, and BL21 (DE3) pLysS, 3 ml 
overnight culture was used to inoculate 100 ml of LB and incubated to reach an OD600 of 
0.6. The cells were centrifuged at 5000 g (Eppendorf 5415D) for 10 minutes at 4°C. The 
pellet was resuspended in 20 ml of cold 50 mM calcium chloride solution and incubated 
on ice for 30 minutes then centrifuged as above. The pellet was resuspended in 5 ml of 50 
mM calcium chloride and 5 ml of 50% glycerol, aliquoted to 200 µl and stored at -80C. 
2.3. Transformation into competent E. coli: 
A volume of 100 µl of the competent cells was incubated on ice after adding 10 µl 
of the transforming DNA for 30 min. Cells were then incubated at 42C for two min for 
heat shock then immediately placed on ice for 10 min. After that, 600 µl of LB was added 
to the cells, and they were incubated shaking at 37C for 90 min. Cells were then plated 
on LB plates with antibiotic as specified for selection and incubated overnight. 
Transformed colonies were patched the next day on a new plate and re-incubated for 6 
hours. Every cell patch was used to inoculate 3 ml LB to grow overnight. Next day, 
aliquots with 25% glycerol were made and stored at -80C. 
2.4. Plasmid extraction and agarose gel electrophoresis: 
Plasmids were extracted from 3 ml LB overnight cultures of the transformed 
DH5α. Cells were centrifuged at 5000 g. The pellet was resuspended in 100 µl of 
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solution I (50 mM glucose, 25 mM Tris-HCl pH 8, 10 mM ethylenediaminetetraacetate 
(EDTA, pH 8). Then 200 μL of Solution II (1% SDS, 0.2 M NaOH), and 350 μL of 
Solution III (3M sodium acetate) were added with gentle mixing of the sample. After 10 
minutes centrifugation at 4000 g, the supernatant was treated with the same volume of 
cold isopropanol and mixed by ten times inversion and incubated at room temperature for 
10 minutes. Samples were centrifuged as above, the pellet washed with 1 ml of cold 70% 
and 100% ethanol. The pellet was left to dry at 37°C and finally resuspended in 50 μl of 
sterile water. DNA samples were analyzed by agarose gel electrophoresis using TAE 
buffer (40 mM Tris-acetate pH 8.3, 1 mM EDTA), 0.7% of agarose gel with 0.01% 
ethidium bromide. Samples in 2 DNA loading buffer (Invitrogen) as well as 1 Kb DNA 
ladder standard (Genedirex) were loaded on the gel and separated at 100 V. UV light was 
used to visualize DNA bands. 
2.5. GDP-manno-heptose synthesis: 
GDP-manno-heptose synthesis from sedoheptulose 7-phosphate (Carbosynth) was 
performed using GmhA/B/C/D enzymes following previously established conditions 
(31). Gmh enzymes were cloned previously from Aneurinibacillus thermoaerophilus into 
pDEST-17 with a histidine tag, for GmhA, GmhB, and GmhC, and into pDEST-15 with a 
GST tag for GmhD (31). After expression and purification (see section  2.12 for details) 
small scale reactions were prepared to test sequential conversion of sedoheptulose 7-
phosphate by each enzyme. A master mix of 120 µl containing 0.5 mM sedoheptulose 7-
phosphate, 200 mM ammonium bicarbonate buffer pH 9.0, 0.52 mM ATP (Sigma) and 
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2.5 mM MgCl2 was equally divided into five reaction tubes. The first reaction has no 
enzyme added as a negative control. The other reactions had 0.2 µmol of either GmhA 
only, GmhA and GmhB, GmhA, B, and C, or all enzymes, also contained GTP (Roche) 
in a total volume of 50 µl. All reactions were incubated at 37C for 12 hours, centrifuged 
at 5000 g for 30 minutes. The supernatant was passed through a 10 kDa cut-off 
centricon and lyophilized. The lyophilized pellet was finally resuspended in 25 µl MilliQ 
water for further analysis. 
A large scale reaction of 15 ml was prepared in two steps. In the first step, the 
reaction contained 2.6 mM sedoheptulose 7-phosphate, 400 mM ammonium bicarbonate 
buffer pH 9.0, 10 mM MgCl2, 2.7 mM ATP, 1.0 µmol of GmhA, GmhB, and GmhC. The 
reaction was incubated at 37C for 12 hours. After incubation, it was centrifuged and 
passed through a 10 kDa cut-off centricon. The flow through was used for the second step 
of the reaction to generate GDP-manno-heptose by the addition of 1.0 µmol of GmhD 
and 1.9 mM GTP. After 12 hours incubation at 37C, the reaction was centrifuged and 
passed through the centricon. The final conversion into GDP-manno-heptose was 
monitored by the capillary electrophoresis. 
2.6. High-performance liquid chromatography analysis (HPLC): 
To analyze various sugar products, anionic exchange HPLC with pulsed 
amperometric detection (PAD) was used on a Dionex ICS 3000 instrument. CarboPac 
PA1 column (4 250 mm; Dionex) was used after it had equilibrated with 100 mM 
NaOH for 10 minutes. The samples from the small scale synthesis of GDP-manno-
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heptose were lyophilized and  resuspended in deionized water (MilliQ-water) and 10 µl 
was injected to the column. A linear gradient from 100- 500 mM of 1M NaOAc in 100 
mM NaOH was applied for 40 minutes at 1 ml/min as reported previously (31). 
2.7. GDP-manno-heptose purification: 
GDP-manno-heptose was purified using anion-exchange chromatography using a 
High Q Econopac 5 ml column (Bio-Rad) as reported previously (31). A linear gradient 
from 50 mM -1 M triethylammonium bicarbonate (TEAB) pH 8.5, was applied for 20 
column volumes at 1 ml/min. Detection of sugar nucleotide was by UV light (260 and 
214 nm). Desired fractions containing the suspected GDP-manno-heptose were pooled 
and lyophilized twice with resuspension in water between both lyophilization steps. 
Finally, they were resuspended in water and analyzed by CE along with previously 
characterized GDP-manno-heptose for product identification and purity assessment. 
Quantitation of GDP-manno-heptose was performed using a Nanodrop 
spectrophotometer using εGTP = 12000 mol-1 L cm-1. 
2.8. Comparative functional analysis: 
A comparative functional analysis between the heptose modifying enzymes and 
well-studied homologous enzymes with known structure was done. The function of 
residues in the binding site was predicted based on structural sequence alignment to 
residues of known function in the homologues. The epimerases were compared to a 
dTDP-hexoluse C3/C5 epimerase (RmlC) from Salmonella enterica and Streptococcus 
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suis (45, 55). The reductases were compared to the GDP-fucose synthetase (GFS), a 
GDP-4-keto-6-deoxy-D-mannose C3/C5 epimerase and C4 reductase from E. coli (55). 
2.9. Structural modeling: 
Homology modeling approach was used to model the structure of the epimerases, 
DdahB and MlghB, and the reductases, DdahC and MlghC. SWISS-MODEL workspace 
(http://swissmodel.expasy.org/) was used to build the structure model for the wild type 
and mutant enzymes (7). In the main page of SWISS-MODEL workspace, the protein 
sequence of the wild type or the mutant was entered in the target sequence field. The 
protein name was written in the project title field then the option of searching for a 
template was chosen. The software then showed a list of templates ordered from the 
highest identity to the target sequence to the lowest identity. On the top of the list, several 
tabs allow the user to check the selected templates before model building. The sequence 
similarity tab shows how similar the selected template is to the target protein. The 
alignment tab shows the protein sequence of the target aligned with the template 
sequence. The user can select more than one template for model building. After template 
selection, model building was started by clicking on build models button. In a new 
window, all build models are shown. The best model was chosen based on the QMEAN 
score and exported from SWISS-MODEL as protein data bank files (PDB) (20). The 3D 
structures were then visualized and analyzed using PyMol software 
(https://www.pymol.org/). 
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2.10. Subcloning and crystallography: 
The epimerase genes ddahB and mlghB were subcloned into a pEHISTEV vector 
for crystallography purposes. The pEHISTEV plasmid was received from Dr. Naismith 
(St Andrews, UK) and transformed into DH5α with kanamycin selection (103). After 
plasmid extraction and purification, cohesive ends were generated by restriction digest 
using 1.0 U of BamHI and NcoI restriction enzymes (BioLabs) and 1REact 3 buffer 
(Invitrogen). Both ddahB and mlghB genes were PCR amplified from pET-ddahB and 
pET-mlghB plasmids by iMax DNA polymerase (iNtRON) and the primers listed in 
Appendix 1 (112). PCR products were then analyzed by agarose gel electrophoresis and 
purified using PCR purification kit following manufacturer’s instructions (Geneaid). PCR 
products were then subjected to restriction cut using AflIII (Invitrogen) and BamHI for 
ddahB, NcoI and BamHI for MlghB in 1REact 3 buffer. To insert the cut PCR product 
into the pEHISTEV vector, reactions containing each insert, the vector, 26 U ligase 
(BioLabs), and 1 ligation buffer were incubated at room temperature overnight. After 
analyzing the products by gel electrophoresis, they were transformed into DH5α. 
Extracted plasmids from recovered clones were sequenced for confirmation using T7 
promoter primer (Roberts Research Institute sequencing facility, London, Ontario). 
The crystallography was done by collaborators, Dr. James Naismith and a PhD. 
candidate, Laura Woodward in St. Andrews’ University, UK. The molecular structure of 
both epimerases DdahB and MlghB were solved by molecular replacement on the crystal 
46 
 
 
 
structure of RmlC. The structure of MlghB/GDP-mannose was solved by co-
crystallization with GDP-mannose as an analog substrate. 
2.11. Site-directed mutagenesis: 
Site-directed mutagenesis was performed following the QuikChange® 
mutagenesis procedure using iMax DNA polymerase. To generate the mutants, reactions 
containing 10 pmol of either the forward or the reverse primer (Appendix 2), 20 ng of the 
template plasmid, and 0.05 U of iMax polymerase in 1 iMax buffer were set up. The 
PCR was programmed to 30 cycles of denaturation at 98°C for 30 seconds followed by 
annealing at each primer annealing temperature, and extension at 72° based on the iMax 
polymerases speed, 1kb/min. After ten PCR cycles, individual reactions containing either 
the forward or the reverse primer were combined, 0.05 U of iMax enzyme was added, 
and PCR was resumed for 20 more cycles and final extension at 72°C for 7 minutes. The 
PCR product was then treated with DpnI (Stratagene) for one hour and transformed into 
E. coli DH5α as explained above. Purified plasmids were sequenced with T7 promoter 
primer for confirmation (Roberts Research Institute sequencing facility, London, 
Ontario). 
2.12. Protein expression and purification: 
The modified heptose synthesis genes, mlghB and mlghC, from C. jejuni 
NCTC11168, and ddahA, ddahB, ddahC from C. jejuni 81-176, were previously cloned 
into pET vector with N-terminus 6 histidine tags (110, 112). The GDP-mannose 
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dehydratase, hp0044 gene, was previously cloned from Helicobacter pylori into pGEX-
2T with N-terminus GST-tag (31). Genes for GDP-manno-heptose synthesis were cloned 
from Aneurinibacillus thermoaerophilus (87). The gmhA, gmhB, and gmhC genes were 
previously cloned into pDEST17 with N-terminus 6 histidine tag, while gmhD was 
cloned into pDEST15 with N-terminus GST tag (31). Expression of all proteins was 
carried using E. coli ER2566, BL21 (DE3) pLysS, or DH5α expression strains (see Table 
1 for specifics). Cells were grown in LB with shaking at 37C to OD600 of 0.6. To induce 
expression 0.1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) was added. For the 
modified heptose synthesis enzymes, 300 ml cultures were induced for three hours at 
37C for MlghB, MlghC, DdahA, DdahC, and at 25C for DdahB. The GDP-mannose 
dehydratase, HP0044, was induced from DH5α at 37C for three hours. For GDP-manno-
heptose synthesis enzymes, 1 L cultures were induced at 25C for three hours for GmhA, 
GmhB, GmhC, and 16 hours for GmhD.  
Purification of all proteins was done using affinity chromatography purification 
using FPLC. For N-terminally histidine-tagged proteins, the expressed cell pellets were 
resuspended in binding buffer (0.1 M NaCl, 20 mM imidazole, 20 mM Tris-HCl) with a 
pH away from the protein isoelectric point (Table 1). After cell disruption under 25 psi 
and ultracentrifugation, the proteins were purified by nickel chelation using a 1.6 ml of 
Poros MC 20 column (4.6 100 mm; Applied Biosystems). After washing the non-
specific binding proteins, His-tagged proteins were eluted using a gradient of imidazole 
concentrations. The GST-tagged GmhD and HP0044 were resuspended in PBS binding 
buffer (140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and 1.8 mM KH2PO4. pH 8.0). 
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They were purified using 1 ml GSTrap FF column (GE Healthcare). Unbound proteins 
were washed with binding buffer. Bound proteins were eluted using 0.01 M reduced 
glutathione (Sigma). Pure protein fractions were preserved in 25% glycerol at -20 C. 
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Table 1: Expression and purification conditions: 
 
* Protein mass with the tag
Strain Gene Vector Tag 
Mass 
(kDa)* 
Purificat
ion pH 
E. coli expression 
strain 
C. jejuni  
NCTC 
11168 
mlghB pET His 22.2 8.0 BL21 (DE3) pLysS 
mlghC pET His 41.7 7.0 ER2566 
C. jejuni 
81-176 
ddahA pET His 40.5 8.0 BL21 (DE3) pLysS 
ddahB pET His 22.1 7.0 BL21 (DE3) pLysS 
ddahC pET His 40.7 7.0 ER2566 
H. pylori hp0044 pGEX-2T GST 73.9 8.0 DH5α 
A. 
thermoae
rophilus 
gmha pDEST17 His 25.0 7.5 
BL21 (DE3) pLysS 
gmhb pDEST17 His 39.1 7.5 
gmhc pDEST17 His 24.7 7.5 
gmhD pDEST15 GST 52.6 8.0 
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2.13. SDS-polyacrylamide gel electrophoresis of proteins: 
SDS-PAGE analysis for proteins was performed using stacking gel (4 % 
polyacrylamide (Bio-Rad, mini-gel system), 125 mM Tris pH 6.8, 0.1 % SDS, 0.5% 
ammonium persulfate (APS), and 0.1 % tetramethylethylenediamine (TEMED)), and 
separating gel (12% polyacrylamide, 375 mM Tris pH 8.8, 0.1 % SDS, 0.1 % APS, and 
0.1 % TEMED). Before loading on the gel, protein samples were incubated for 10 min at 
100C in SDS loading buffer (0.625 M Tris pH 6.8, 2% SDS, 2% β-mercaptoethanol, 
10% glycerol, and 0.002% bromophenol blue). Gels were run in Tris-glycine running 
buffer (25 mM Tris, 190 mM glycine, 1% w/v SDS. pH 8.3) at 10 mA through stacking 
gel and 20 mA through the separating gel. Proteins were visualized by Coomassie blue 
staining (10% acetic acid, 25% ethanol, 0.001% (w/v) Coomassie blue). 
2.14. Western blotting: 
Western blotting was performed after SDS-PAGE. Proteins were transferred from 
the gel to a nitrocellulose membrane (Bio-Rad). The transfer was performed for 45 
minutes in Tris-Glycine Transfer buffer (192 mM glycine, 25 mM Tris pH 8.3, 20% 
methanol, 0.01% SDS) with a constant current of 180mA (Bio-Rad transblot system). 
After transfer, the membrane was washed with water and stained with 0.1% Ponceau S 
Red to visualize the transferred proteins. After scanning the membrane, the Ponceau stain 
was washed by 1 PBS buffer (137 mM NaCl, 2.7 mM KC1, 8 mM Na2HPO4, and 1.46 
mM KH2PO4, pH 7.2). The membrane was blocked with 5% skim milk in 1 PBS buffer 
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overnight at 4C, or 2.5% for 30 minutes at room temperature. After blocking, the 
membrane was washed twice in PBS-Tween-20 (PBS and 0.1% Tween-20) and once in 
PBS buffer for 5 minutes each. Primary antibody (Sigma) was added to the membrane 
and incubated for one hour. After washing twice in PBS-Tween-20 and once with PBS, 
the secondary antibody (Sigma) was added and incubated 40 minutes in the dark. See 
Appendix 3 for the list of antibodies used. Finally, the membrane was washed again as 
above and the protein was visualized using Licor Infrared Imaging system at wavelengths 
of 700nm or 800nm. 
2.15. Bradford assay: 
Total protein concentration was measured from pure protein fractions before 
adding the 25% glycerol. The assay standard curve was made using serial dilutions of 
bovine serum albumin (BSA). The procedure was performed according to the 
manufacturer’s instructions (Bio-Rad). Absorbance was taken at 595 nm. All samples 
were measured in triplicate. 
2.16. The epimerases reactions and kinetics: 
2.16.1. GDP-manno-heptose reactions: 
To test the activity for the epimerases, a master mix of 80 µl containing 0.17 mM 
GDP-manno-heptose, 1.5 µmol DdahA, 200 mM Tris pH 7.5, and 0.13 mM NADP+ that 
was used as an internal standard to facilitate peak alignment on the capillary 
electrophoresis (CE) electeropherograms. The master mix was incubated at 37C for 30 
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minutes then frozen at -20C before further usage. The total conversion of GDP-manno-
heptose into the desired substrate for the epimerases (P1) was confirmed by testing an 
aliquot from the master mix using CE. The master mix was then divided into nine tubes, 
8 µl each. To each tube, 1.0 pmol of either MlghB or DdahB, wild type or mutants were 
added. All reaction tubes were incubated at 37C for 30 minutes. At the end of the 
incubation, they were frozen at -20C. 
The kinetics were performed with the same substrate and enzymes concentrations 
in master mixes as mentioned above. The reactions were incubated for 5, 10, 15, 20, 30, 
and 45 minutes. At each time point, the reactions were snap frozen in dry ice/ ethanol 
mixture and individually analyzed by CE. 
2.16.2. GDP-mannose reactions: 
For the epimerases, a master mix of 80 µl containing 0.77mM GDP-mannose, 2.0 
pmol HP0044, 200 mM Tris pH 7.5, and 0.1 mM NADP+ was incubated at 37C for 90 
minutes. After the total conversion of GDP-mannose into P1’ was confirmed by CE, the 
mix was frozen at -20C then divided into nine tubes, 8 µl each. For each tube 5 pmol/ul 
of DdahB or 1 pmol/ul of MlghB, wild type or mutants was added. Reaction tubes were 
incubated one hour for MlghB and 5 hours for DdahB at 37C. 
The kinetics were performed only for MlghB with the same substrate and 
enzymes concentrations in master mixes as mentioned above. The reactions were 
incubated for 20, 30, 60, 150, 240, and 300 minutes. At each time point, the reactions 
were snap frozen in dry ice/ ethanol mixture and individually analyzed by CE 
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2.17. The reductases reactions and kinetics: 
2.17.1. GDP-manno-heptose reactions: 
To test the activity of the reductases, a master mix of 56 µl containing 0.17 mM 
GDP-manno-heptose, 1.5 µmol DdahA, 2 pmol MlghB, 200 mM Tris pH 7.5, and 0.5 
mM NADPH as a co-factor for the reductases. The master mix was incubated at 37C for 
30 minutes then frozen at -20C. An aliquot tested by CE for the generation of the 
epimerized sugar nucleotide by MlghB, P4α, P4β, and P4γ. The master mix was then 
divided into six tubes, 8.0 µl each, and 1.0 pmol of either MlghC or DdahC, wild type or 
mutants was added. Reactions were incubated at 37C for 30 minutes then frozen -20C. 
To test the substrate specificity of the reductases, wild type and mutants, a base 
reaction containing 0.17 mM GDP-manno-heptose, 1.5 µmol DdahA, 2 pmol MlghB, 200 
mM Tris pH 7.5, and 0.5 mM NADPH as a co-factor for the reductases. The master mix 
was incubated at 37C for 30 minutes then frozen at -20C. An aliquot tested by CE for 
the generation of the epimerized sugar nucleotide by MlghB, P4α, P4β, and P4γ. The 
master mix was then ultrafiltered to remove MlghB from the reaction using a 10 kDa 
cutoff centricone. The filtrate was eluquted and 1.0 pmol of either MlghC or DdahC, wild 
type or mutants was added. Reactions were incubated at 37C for 30 minutes then frozen 
-20C then analyzed by CE. The same method was used to perform the kinetics of the 
reductases. The same concentrations of the substrate and the enzymes were used to 
incubate the reductases, wild type and mutants for 7 time points, 5, 10, 15, 20, 30, 45, and 
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60 minutes at 37C. All reactions were snap frozen in dry ice/ ethanol mixture at each 
time point and individually analyzed by the CE. 
2.17.2. GDP-mannose reactions: 
The activity of the reductases was tested on different GDP-mannose substrates in 
two different reaction sets. The activity of the wild type DdahC and MlghC were tested 
on both P4’ and P1’, as well as on P1’ by itself. For the first set, a master mix of 30 µl 
containing 1.25 mM GDP-mannose, 2.0 pmol HP0044, 2.0 pmol MlghB, 200 mM Tris 
pH 7.5, and 0.5 mM NADP+ was incubated at 37C for 90 minutes. After the total 
conversion of GDP-mannose into P1’, and formation of P4’ was confirmed by CE, the 
reaction was divided where 1.0 pmol of DdahC or MlghC were added and incubated for 
60 minutes at 37C then frozen -20C then analyzed by CE. 
The second set was to test the activity on P1’ only. A base reaction containing 
0.77 mM GDP-mannose, 2.0 pmol HP0044, 200 mM Tris pH 7.5, and 0.1 mM NADP+ 
was incubated at 37C for 90 minutes. After the total conversion of GDP-mannose into 
P1’ was confirmed by CE, the mix was ultrafiltered to remove HP0044 from the reaction. 
The filterate was divided and 1.0 pmol of eather DdahC or MlghC was added and 
incubated for 60 minuts at 37C then frozen -20C then analyzed by CE.  
To test the differences between the wild and the mutants of DdahC and MlghC, a 
reaction containing 0.77 mM GDP-mannose, 2.0 pmol HP0044, 200 mM Tris pH 7.5, 
and 0.5 mM NADP+ was incubated at 37C for 90 minutes and ultrafiltered after total 
conversion of GDP-mannose into P1’. 
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The kinetics were performed in a similar reaction to the first set mentioned above. 
The reactions were incubated for 10, 20, 35, 50, 70, and 95 minutes at 37C. All reactions 
were snap frozen in dry ice/ ethanol mixture at each time point and individually analyzed 
by the CE. 
2.18. Capillary electrophoresis analysis: 
Capillary electrophoresis for sugar nucleotides analysis was performed on a 
Beckman MDQ/ Gold instrument using the 32 Karat software and 57 cm bare silica 
capillary. The sample running method includes initial washing of the capillary with 200 
mM Borax buffer pH 9.0 for two minutes at 20 psi, followed by four seconds of sample 
injection. The separation of the sample was done under 26 kV and detection was at 254 
nm. After each sample, the capillary was washed for two minutes with water, two 
minutes with 0.1M NaOH, and two minutes with water again. Using the 32Karat 
software, product formation was estimated by integration of surface areas under the 
substrate and product peaks. 
2.19. Biofilm assay: 
The wild-type strain, C. jejuni NCTC11168, was tested for biofilm formation 
along with four heptose biosynthesis mutants and a capsule-less mutant that were 
generated previously in our lab, wcaG::cat, mlghC::cat, mlghB::cat, and wcaGΔ::cat 
(184). KpsM::kan that is known to be a capsule-less strain was used as a negative control. 
All strains were grown as explained in section  2.1. In a 100mm diameter glass tube, one 
ml of a cell suspension adjusted to OD600 of 0.7 was incubated under aerobic or 
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microaerobic static conditions at 37°C for 3 days. Three replicates were prepared for each 
strain. After the three days incubation, a set of tubes was taken out of the incubator every 
day for four days, washed three times with water to remove planktonic cells, and left to 
dry for 30 minutes. To stain biofilm, 1 ml of 1% crystal violet was added to each tube and 
incubated at room temperature for one hour. Excess stain was washed with water three 
times, and the tubes were left to dry for 30 minutes. Finally, the stained biofilms were 
detached from the glass wall by adding 1 ml of 30 % acetic acid and incubating for an 
hour. Two hundred µl of each sample were transferred to a 96-well microtiter plate to 
measure the absorbance at 950 nm (146). Statistics were done using one-way ANOVA 
test for two independent experiments. 
2.20. Hitchcock and Brown method for CPS and LOS extraction: 
The cell pellets from 1 ml of the same cell suspensions that were used for the 
biofilm assay were washed and resuspended in lysis buffer (2% SDS, 4% 2-
mercaptoethanol, 10% glycerol, 1 M Tris pH 6.8), and bromophenol blue). After heating 
the sample at 100C for 30 min, it was treated with 2.5 µg of proteinase K (Roche) at 
60C for an hour (69). Finally, 15 µl of the sample were loaded on SDS gels with Tris-
Glycine buffer as explained bellow. 
2.21. SDS-polyacrylamide gel electrophoresis for CPS: 
SDS-PAGE analysis for CPS samples was performed using stacking gel (4 % 
polyacrylamide, 125 mM Tris pH 6.8, 0.1 % SDS, 0.5% APS, and 0.1 % TEMED), and 
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separating gel (14% polyacrylamide, 3 M Tris, 1 M HCl, and 0.3% SDS buffer, pH 8.4, 
0.1% APS, and 0.1 % TEMED). CPS cell suspensions were treated according to 
Hitchcock and Brown method or saline extraction as explained above then loaded. The 
gel was run in Tris-glycine buffer at 20 mA. The CPS was finally visualized by silver 
staining as explained below. 
2.22. Silver staining: 
Silver staining of the carbohydrate samples that were separated by SDS-PAGE  
was done according to Fomsgaard et al protocol (51). The gels were incubated shaking in 
oxidizing solution (0.7% periodic acid, 40% ethanol and 5% acetic acid in MilliQ water) 
at room temperature for 20 minutes. They were then washed four times over 15 minutes 
with MilliQ water. After washing, the gels were stained with staining solution (0.19% 
(v/v) 10 N NaOH, 1.3% (v/v) ammonium hydroxide, 0.7% (w/v) silver nitrate) for 10 
minutes, followed by five washes with MilliQ water. The gel was developed in 0.005% 
(w/v) citric acid and 0.05% (v/v) formaldehyde (37%) until bands became visible. 
Finally, they were washed with MilliQ water and scanned.
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3.1. GDP-manno-heptose synthesis: 
The synthesis of GDP-manno-heptose from sedoheptulose-7-phosphate was done 
following previously optimized conditions using GmhA, GmhB, GmhC, and GmhD 
enzymes (31). GmhA, GmhB, and GmhC are histidine-tagged proteins and were purified 
using nickel affinity chromatography. GmhD is GST-tagged and was purified by GST 
affinity chromatography (Figure 8-A). 
The synthesis of GDP-manno-heptose was initially carried on a small scale to 
monitor the activity of the purified biosynthesis enzymes, GmhA, GmhB, and GmhC. 
Because the last enzyme in the pathway, GmhD, has a very short lifespan, it was not 
tested in the small scale analysis. Based on the HPLC analysis, the conversions of 0.5 
mM sedoheptulose-7-phosphate into heptose-7-phosphate by GmhA was successful, but 
not complete (Figure 8-B). The reaction where both GmhA and GmhB along with ATP 
were used showed complete conversion of the sedoheptulose-7-phosphate into heptose-
1,7-biphosphate. Adding all the three enzymes, GmhA, GmhB, and GmhC resulted in the 
formation of the heptose-1-phosphate (Figure 8-B). In a large scale, 5.4 mM of the 
sedoheptulose-7-phosphate was used to generate the heptose-1-phosphate using 5 μmol 
of GmhA, GmhB and GmhC. The products formation was analyzed by HPLC using 
sedoheptulose-7-phosphate as a standard. The products migration time was assessed 
based on the previously established methods where the products were identified by mass 
spectrometry analysis (31).
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Figure 8: Synthesis of GDP-manno-heptose in small scale. A. SDS-PAGE analysis 
of the purified GDP-manno-heptose synthesis enzymes. From 1 to 4, showing GmhA 
(25 kDa), GmhB (38 kDa), GmhC (25 kDa), and GmhD (52 kDa). The left panel 
shows the Coomassie blue stain, while the right panel shows the anti-histidine 
western blot, for GmhA, GmhB, and GmhC, as well as the anti-GST tag western blot 
for GmhD. B. HPLC chromatograms of small scale sequential conversion of 
sedoheptulose-7-phosphate into heptose-1-phosphate.  GmhA converts 
sedoheptulose-7-phosphate (S7) into heptose-7-phosphate (H7) (trace b). GmhB 
converts H7 into heptose-1,7-biphosphate (H1,7) by adding phosphate group from 
ATP molecule that was provided in the reaction (trace c). GmhC removes one 
phosphate from H1,7 to generate heptose-1-phosphate (H1) (trace d). The sugar peaks 
are labeled in red, and their chemical structures are represented. 
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3.2. Epimerases comparative functional analysis and structure: 
3.2.1. Comparative functional analysis:  
 The analysis of the active site of DdahB, a C3 epimerase, and MlghB, a 
C3/C5 epimerase, was based on the knowledge obtained from studied RmlC enzymes 
(45, 46, 55). RmlC, a dTDP-6-deoxy-D-xylo-4-hexulose C3/C5 epimerase, is the third 
enzyme in the dTDP-L-rhamnose synthesis pathway. RmlC substrate has a 4-keto 
group that is important to initialize the epimerization. In St. suis’s RmlC, Asn127 
recognize the O4-keto group and binds it through the amide group, which lowers the 
pKa of the protons attached to C3 and C5 (4, 45). The epimerization at C3 and C5 is 
obtained in two chemical steps, deprotonation from one face of the sugar ring 
followed by reprotonation at the opposite face at C3 and C5 position (45, 46). 
Deuterium incorporation analysis indicates that RmlC could perform sequential C5, 
C3 epimerization where C5 epimerization is faster than C3 epimerization (46). The 
C3/C5 epimerized product that is generated by RmlC could not be detected in a 
chemical reaction or directly quantified by biochemical assays (60, 118, 163). The 
activity of RmlC was rather confirmed by coupled assay with the downstream 
reductase, RmlD, by measuring the conversion rate of NADPH upon formation of 
dTDP-L-rhamnose (46, 60). The explanation of why the RmlC product has never 
been isolated is that it can exist only as an enzyme-bound intermediate that can only 
disassociate after reduction by RmlD, which could form a complex with RmlC (118).  
  The residues that are involved in RmlC activity, His63-Asp170 dyad, Tyr133, 
and Lys73, were identified in S. enterica’s RmlC by structural and biochemical 
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assays (46). These residues are highly conserved among studied RmlC enzymes in 
other bacteria. The His63-Asp170 dyad is important for both C3 and C5 
epimerization of the substrate. Based on deuterium incorporation and mutagenesis 
coupled with enzymes assays, His63Ala is catalytically inactive. This, together with 
its location in the binding site suggests that His63 acts as a base to deprotonate the 
sugar from the lower face of the ring at C3 and C5 positions, as it has a flexible side 
chain conformation (45). The proton abstraction results in the formation of an enolate 
anion that could be stabilized by Lys73 (45, 46). At the opposite face of the sugar 
ring, Tyr133 donates a proton at C5 position. Tyr133Phe had 1000 fold reduction in 
activity and some deuterium incorporation only at C3 but not at C5. This indicates 
that the hydroxyl group of the Tyr133 side chain is essential for C5 but not for C3 
epimerization. A conserved water molecule found close to C3 could be compensating 
for Tyr133 function in the Tyr133Phe mutant by donating a proton (46). On the other 
hand, Lys73Ala had 100 fold reduction in activity and a small amount of deuterium 
incorporation at C5 but not at C3, suggesting that Lys73 is essential for epimerization 
at C3 (46).  
 Based on co-crystallography of S. enterica’s RmlC with dTDP-phenol, the 
residues that are involved in the ribose nucleotide binding are Phe27, Tyr139, Asn50 
and Phe20 (55). The thymidine ring is stacked between the aromatic residues Phe27 
and Tyr139. Asn50 is also interacting with the thymidine ring, while Phe20 from B 
monomer stacks against the ribose ring of the nucleotide. The residues that  interact 
with the sugar ring, Asn127, Phe129, and Tyr138, were identified in St. suis’s RmlC 
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(45). The Asn127 residue is important for the 4-keto substrate recognition by binding 
to O4, which predicted to lower the transition state energy of C3 and C5 protons, 
while both Phe129 and Tyr138 make Van der Waals interactions with C6 and O6. 
The last two residues, Phe129 and Tyr138, are conserved among RmlC enzymes as 
aromatic residues and most commonly found as Phe/Phe pair, which means that they 
could be involved in stacking interactions with the sugar (54). 
 Similar to RmlC, C. jejuni NCTC 11168 epimerase, MlghB, is able to perform 
C3/C5 epimerization on a different substrate, GDP-6-deoxy-4-keto-D-lyxo-heptose. 
However, MlghB can release the three epimerized products that were detected by 
capillary electrophoresis and identified by mass spectrometry (111). On the other 
hand, the epimerase in C. jejuni 81-176, DdahB, can only epimerize the GDP-6-
deoxy-4-keto-D-lyxo-heptose at C3 generating one product under same conditions as 
MlghB (111, 112). Based on sequence alignment with  St. suis’s and S. enterica’s 
RmlC with, both DdahB and MlghB  have the conserved catalytic His67-Asp173 
dyad, Tyr134, and Lys74 residues (the numbers are for DdahB and MlghB protein 
sequences) (Figure 9) (Table 2). Therefore, His67 is predicted to be catalytic for 
epimerization at C3 and C5 of the heptose substrate. On the other hand, Tyr134 and 
Lys74 could be essential for epimerization at C5 and/or C3. Similar to RmlC’s 
nucleotide binding residues, Phe27, Tyr139, Asn50 and Phe20 both DdahB and 
MlghB have the residues that could be important for the nucleotide binding, Ile31, 
Tyr142, Lys54, and Phe24. Aligned with the residue Asn127 that bind the 4-keto 
group of the sugar ring in RmlC, DdahB and MlghB have Asn121. Therefore, it could 
65 
 
 
 
be involved in the recognition of the 4-keto group of the substrate. Replacing the 
Phe129 and Tyr138 in S. enterica’s RmlC, which are usually found as Phe/Phe pair in 
other RmlC enzymes, DdahB and MlghB have His123 and Tyr132. Both residues 
could function for catalysis or for stacking reaction with the substrate (32, 54, 55). In 
S. enterica’s RmlC, there is a second His120-Asp84 dyad with unknown function that 
is not conserved among other RmlC (46, 55). Conversely, in DdahB and MlghB the 
aspartic acid is substituted by Gln85 that is positioned in close location to interact 
with Asn121 through the amide group by a hydrogen bond (21, 63). This interaction 
could be important for catalysis (45, 46, 55). The residues Asn121, His67, Tyr134, 
Tyr132, and Lys74 have been targeted for mutagenesis to test their predicted function 
in catalysis. 
3.2.2. Site-directed mutagenesis: 
Five and six mutants were successfully generated for DdahB and MlghB 
respectively using a pET construct that was cloned previously in the lab, some of 
which were generated by other lab members as indicated in Table 3 (112). The table 
shows the rational of each mutant and the substituted amino acid. Asn121 that was 
predicted to recognize the substrate by binding to O4 was mutated into serine, which 
has a shorter side chain, lacks the amide group but has conserved polarity. For the 
His67, two mutants were generated. It was mutated into alanine, which has a non-
functional side chain, or into asparagine to conserve the polarity (46). The Tyr134, as 
well as Tyr132, were mutated into phenylalanine to conserve the aromatic structure 
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and eliminate the hydroxyl function (46). Finally, Lys74 was mutated  into alanine to 
eliminate the function of the side chain (46).  
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Table 2: Comparative functional analysis of the conserved residues in the 
epimerases binding site: 
RmlC 
St. suis 
Function (45) 
RmlC 
S. enterica 
Function (46, 
55) 
DdahB 
MlghB 
C. jejuni 
Predicted 
function 
H76 
Catalytic. Acts 
like a base for 
epimerization at 
C3 and C5 
H63 
Catalytic. Acts 
like a base for 
epimerization at 
C3 and C5 
H67 
Catalytic  for 
epimerization at 
C3 and C5 
D180 
His76-Asp dyad. 
Increases basicity 
of H76  
D170 
His63-Asp dyad. 
Increases basicity 
of H63 
D173 
Catalytic His67-
Asp dyad. 
Y140 
Catalytic. The 
OH group is 3.7Å 
from C3 and 
3.5Å from C5. 
Y133 
Catalytic. Proton 
donor for 
epimerization at 
C5 and not 
essential at C3 
Y134 
Catalytic for  
epimerization at 
C3 and C5 
K82 
Catalytic. 
Stabilizes the 
negative charge 
after 
deprotonation 
K73 
Catalytic. For 
epimerization at 
C3 
K74 
Catalytic for 
epimerization at 
C3 
F36 
Interact with 
thymidine ring. 
F27 
Interact with 
thymidine ring. 
I31 
Interact with 
thymidine ring. Y145 Y139 Y142 
N63 N50 K57 
H29 
Stacks against 
the ribose ring. 
F20 
Stacks against 
the ribose ring. 
F24 
Stacks against 
the ribose ring. 
N127 
Binds O4 
(substrate 
recognition) 
H120 
Unknown. Could 
interact with O4 N121 
Binds O4 
(substrate 
recognition) 
F129 
Makes VDW 
interactions with 
C6 and O6. not 
conserved in all 
RmlC 
F122 Unknown H123 
Interact with the 
sugar ring 
Y138 F131 Unknown Y132 Catalytic 
G94 Unknown D84 
His120-Asp 
dyad. Unknown 
function 
Q85 
Catalytic. 
Possible 
interaction with 
N121 (63). 
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Figure 9: Protein sequence alignment of the epimerases. Alignment of both RmlC 
enzymes from S. suis and S. enterica with C. jejuni epimerases DdahB and MlghB 
sequences. The residues of interest are highlighted, and the numbering is for C. jejuni 
epimerases. 
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3.2.3. Structure modeling: 
Since the experimental approaches could be unsuccessful and time consuming 
to solve the structure of some proteins, the structural modeling was used because it is 
a feasible approach to solve the molecular structure of DdhaB and MlghB. 
The best template for DdahB and MlghB used for modeling from SWISS-
MODEL workspace was within the highest QMEAN scoring templates (20). They 
were modeled on dTDP-6-deoxy-D-xylo-4-hexulose C3/C5 epimerase (RmlC) from 
S. enterica (PDB code 1DZR) (55). The resolution of the template is 2.17 Å. The 
overall structure of both DdahB and MlghB showed that they are dimeric and highly 
similar (Figure 10-A). Based on the structural alignment with RmlC, the sugar-
nucleotide binding site is located in the accessible cavity between the β-sheets within 
each monomer (Figure 10-B). The residues in the binding site that are predicted to 
have a role in substrate binding or catalysis based on the comparative functional 
analysis have been represented in the model (45, 55). 
The fact that DdahB can only epimerize at C3 in the same conditions as 
MlghB whereas MlghB can do either or both epimerization at C3/C5 suggests two 
hypotheses. The first is that DdahB could be lacking the catalytic residues that 
function for C5 epimerization. No significant difference between the conserved 
catalytic residues in DdahB and MlghB active site based on structural alignment. 
Furthermore, most of the non-conserved residues had small hydrophobic side chains. 
In fact, it has been shown previously in our lab that under prolonged incubation 
conditions and high concentration of DdahB, DdahB can perform limited C5 
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epimerization generating small amounts of the C5 and C3/C5 epimers. This means 
that it has the functional residues to perform C5 epimerization. The second hypothesis 
is that DdahB could have less flexible conformation of the active site than MlghB. 
Several studies have shown that homologous enzymes with conserved active site 
sequences can perform different catalysis (17, 53, 138). This feature was referred to 
as active site flexibility, which allows specific enzymes to perform specific functions 
based on the conformational changes that occur upon substrate binding or during the 
catalysis (89, 180). 
 To look for possibility of side chain conformational changes and 
compensation upon mutation, the mutants were also modeled. The mutants’ models 
were obtained by modeling the mutated protein sequence in SWISS-MODEL rather 
than replacing the side chain in the modeled wild type enzyme. The wild type model 
was superimposed with each mutant model. Based on the superimposed structure, all 
mutants’ models showed no differences in the highlighted residues’ conformation 
compared to the wild type, except for two mutants of MlghB, Y134F and N121S. 
Both mutants showed changes in the orientation of Tyr132 (Figure 12). This indicates 
that Tyr132 could have a flexible orientation of its side chain.  
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Table 3: SDM list for the epimerases: 
 
Epimerases Mutation Rational 
Rational of the 
substitution choice 
DdahB N121S* 
Substrate 
recognition 
(binds O4)  
Shorter with no 
amide group and 
conserved polarity. 
 H67A 
Catalytic, 
inactivate. 
No functionality. 
 H67N 
Catalytic, 
inactivate. 
Conserved polarity  
 Y134F ** 
Catalytic, 
inactivate. 
Conserved structure 
with no 
functionality. 
 K74A 
Catalytic, 
inactivate. 
No functionality. 
MlghB N121S* 
Substrate 
recognition 
(binds O4) 
Shorter with no 
amide group and 
conserved polarity. 
 H67A* 
Catalytic, 
inactivate. 
No functionality. 
 H67N 
Catalytic, 
inactivate. 
Conserved polarity 
with no charge. 
 Y134F* 
Catalytic, 
inactivate. 
Conserved structure 
with no 
functionality. 
 Y132F* 
Catalytic, 
inactivate. 
Conserved structure 
with no functionality  
 K74A 
Catalytic, 
inactivate. 
No functionality. 
 
  *SDM done by Michael Roubakha, 2013 
** SDM done by Chelsea Kubinec, 2015 
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 Figure 10: The tertiary and quaternary structure model for the epimerases 
compared to the crystallography structure of RmlC. A. Ribbon representation of 
the superimposed structure model for both DdahB and MlghB shown as a dimer 
where (A) monomer is in yellow and (B) monomer is in blue. N and C annotate the N 
and C termini respectively. The sugar-nucleotide binding site in both monomers is 
indicated by a double arrow. B. Ribbon representation of RmlC crystallography 
structure from S. enterica in gray ribbon with dTDP-phenol, a substrate analog, in 
orange spheres (PDB code 1DZR).
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 Figure 11: The epimerases binding site structure model compared to the binding 
site of RmlC. Ribbon and stick representation of the residues that are predicted to be 
involved in catalysis or substrate binding A. DdahB model B. MlghB model. No obvious 
differences were noted between the conserved residues in the binding site of both DdahB 
and MlghB. C. The binding site structure of RmlC from S. enterica (PDB code 1DZR). 
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Figure 12: MlghB mutants structure model. Ribbon and stick representation of 
the superimposed structure of MlghB WT in cyan, and mutants in red. A. Change 
of Tyr132 orientation in Y134F mutant. B. Change of Tyr132 orientation in N121S 
mutant.  
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3.2.4. Crystallography: 
The crystallography data was obtained from Laura Woodward (Dr. James 
Naismith, St. Andrews University, UK). Both DdahB and MlghB crystal structures are 
solved by molecular replacement using S. enterica’s RmlC crystallography data. The 
resolution of DdahB and MlghB structures is 1.9 Å and 2.3 Å, respectively. There was no 
difference in the location and orientation of the conserved residues between DdahB and 
MlghB binding sites except for the Asp173, which could form a chemical dyad with 
His67 (Figure 13). In DdahB, Asp173 is conserved in the protein sequence but its 
location is not conserved. If this His67/Asp173 dyad is important for C5 epimerization, 
this may explain why DdahB cannot perform it like MlghB. By overlying the 
crystallography structure with the modeling by superimposing both structures , it can be 
concluded that the homology modeling approach is feasible to identify the overall 
structure of the enzymes active sites. However, the limitation is the slight inaccuracy of 
some side chains orientation, such as Tyr132, Tyr134, and Asn121. MlghB was co-
crystallized with GDP-mannose as an analog substrate to identify the possible substrate 
binding residues (Figure 13-C) (Figure 15). The electron density map of the mannose ring 
was not included in the final structure because it can occupy a wide range of positions in 
the binding site resulting in a very low electron density map, but the GDP portion could 
be detected. MlghB/GDP-mannose co-crystal structure revealed the possible interaction 
of the residues highlighted in Table 2 with the substrate. In addition, it sheds light on 
residues that bind the GDP, Ile32, Tyr142, Lys54, and Phe24. Additional residues were 
identified including Asp144 and the N-terminus of the B monomer Met1 (Figure 15).
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Figure 13: The epimerases binding site crystallography structure (Laura 
Woodward and Dr. James Naismith). Ribbon and stick representation of the residues 
in the sugar-nucleotide binding site. A. DdahB binding site. B. MlghB binding site. C. 
Side view of MlghB binding site with the GDP molecule in orange, showing the 
residues that could be involved in the catalysis and substrate binding. 
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Figure 14: Comparison between the modeling and the crystallography structures of 
the binding site of the epimerases. The right panel shows the modeling while the left 
panel shows the crystallography structures (Laura Woodward and Dr. James Naismith) 
of DdahB and MlghB binding site. One of the differences observed is the DdahB 
Asp173 that is not conserved in location as shown in crystallography. The other 
difference is the orientation of the side chains of some residues.
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Figure 15: GDP binding in MlghB. The structure of MlghB and MlghB/GDP-mannose 
(Laura Woodward and Dr. James Naismith). A. MlghB structure docked with GDP-
mannose electron density map in gray net. B. MlghB/GDP-mannose co-crystal structure. 
GDP molecule is in orange. The loop and the residues that are involved in GDP binding 
are in purple. N annotates the N-terminal end of MlghB.  
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3.3. Reductases comparative functional analysis and structure: 
3.3.1. Comparative functional analysis:  
The analysis of the active site of the C4 reductases, DdahC and MlghC, was based 
on the knowledge obtained from GFS, GDP-4-keto-6-deoxy-D-mannose C3/C5 
epimerase, C4 reductase, from E. coli (99, 157, 158). The remarkable feature of GFS 
enzyme is its ability to catalyze three distinct reactions within a single active site to 
generate GDP-L-fucose. These include epimerizations at C3 and C5, as well as an 
NADPH-dependant reduction at C4 of the 4-keto substrate (99). The initial step is 
deprotonation at C3 from one face followed by reprotonation on the other face of the 
sugar ring to generate the first product. This product is then epimerized at C5 by 
deprotonation from one face and reprotonation from the other. Finally, an NADPH-
dependant reduction converts the C3/C5 epimer into GDP-L-fucose by converting the C4 
carbonyl into a hydroxyl group (99). Based on crystallography, GFS is a member of the 
short-chain dehydrogenase reductase (SDR) family (79). The substrate binding domain 
include a pocket forming hydrophobic residues to bind the GDP, Leu184, Val201, and 
Val180, as well as Trp202 that moves after the substrate binding to cover this pocket (99, 
157). GFS possesses the catalytic triad, Ser107, Tyr136, and Lys140 (SYK), which is 
characteristic of SDR enzymes (79). Tyr136 protonates the C4 carbonyl during the 
reduction step (99). The Ser107 and Lys140 are important to lower the pKa of the 
catalytic Tyr136, which allows it to function as a general acid or base during catalysis 
(157). In addition, two catalytic residues that are not conserved among SDR members 
were identified by modeling coupled with mutagenesis, Cys109 and His179. Both 
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residues are implicated in the epimerization reaction (99). Other residues were predicted 
to interact with the sugar ring based on structural modeling, Ser108 and Asn165. 
However, their role in catalysis is unknown.  
DdahC and MlghC are predicted to be C3/C5 epimerases and C4 reductases. 
However, based on biochemical studies conducted in our lab, it has been shown that they 
only perform the C4 reduction on the already epimerized 4-keto form of GDP-manno-
heptose (111). Based on sequence alignment of E. coli GFS with C. jejuni reductases, 
DdahC and MlghC substrate binding domain contain the hydrophobic residue that make 
the GDP binding pocket, Ile185, Ile231, and Val181, as well as Trp232 that could be 
involved in covering the substrate after binding as observed in GFS (DdahC numbering). 
The substrate binding domain of DdahC possesses the same SYK catalytic triad that 
found in GFS, Ser108, Tyr137, and Lys141 (DdahC numbering). However, MlghB has 
both Lys140 and Ser107, but not the tyrosine residue of the triad (MlghC numbering). 
Instead, a phenylalanine was found based on the sequence alignment (Figure 16) (Table 
4). Aligned with the His179 and Cys109 in GFS, which are predicted to be catalytic 
residues for the epimerization, DdahC has His180 and Thr110 while MlghC has Arg181 
and Tyr109. The residues that are predicted to interact with the sugar ring are Asn166 and 
Thr109 in DdahC, Asn165 and Gly108 in MlghC. The hydrophobic guanidine pocket 
forming residues are found in both DdahC and MlghC. The sequence alignment also 
showed that there is an extra sequence of 29 amino acids in DdahC and MlghC not found 
in GFS, which could correspond to a specific structural motif (Figure 16).  
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It has been shown that DdahC and MlghC are highly specific in their choice of 
substrate, and both generate different products (111). The fact that the catalytic residues 
are not conserved between DdahC and MlghC suggests that they could be involved in the 
substrate and products specificity. Therefore, the catalytic residues in DdahC His180 and 
Thr110 have been targeted for  mutagenesis to test their role in specificity. Although 
these residues are predicted to catalyze epimerization reactions, DdahC and MlghC do 
not perform epimerization reaction on their substrates (111). Thus, His180 and Thr110 
could be only involved in substrate binding and specificity.
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Table 4: Comparative functional analysis of the conserved residues in the reductases 
binding site: 
 
  
GFS 
E. coli 
Function (99) 
DdahC 
C. jejuni 
MlghC 
C. jejuni 
Predicted function 
S107 
Catalytic triad for 
reduction at C4 
S108 S107 Catalytic triad in 
DdahC. M110 
instead of F136 in 
MlghB based on the 
structure. 
Y136 Y137 F136 
K140 K141 K140 
C109 
In suitable position 
as a general acid or 
base for the 
epimerization at C3 
and C5. 
T110 Y109 
Catalytic 
H179 H180 R181 
S108 
Predicted to interact 
with the sugar ring 
T109 G108 
Interact with the 
sugar ring 
N165 N166 N165 
L184 
Hydrophobic pocket 
for the guanidine 
ring of the 
nucleotide 
I185 L184 
Hydrophobic pocket 
for the guanidine ring 
of the nucleotide 
V201 I1231 I230 
V180 V181 V180 
W202 W232 W233 
G67 Unknown G68 C68 
Located close to the 
co-factor. Could be 
important for 
binding. 
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Figure 16: Protein sequence alignment of the reductases. Alignment of GFS from E. 
coli with C. jejuni reductases DdahC and MlghC protein sequence. The residues of 
interest are highlighted, and the numbering is for DdahC. In red box is the 29 amino acid 
sequence that is found in C. jejuni reductases but not in GFS. 
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3.3.2. Reductases structure modeling: 
Within the highest QMEAN scoring templates for DdahC and MlghC, the GDP-4-
keto-6 deoxy-mannose C3/C5 epimerase, C4 reductase GFS from E. coli was used as a 
template (PDB code 1BSV) (157). The resolution of GFS structure is 2.20 Å. Both 
reductases structures were similar to each other and existed as dimers (Figure 17). 
Nevertheless, there were unstructured loops that are not found in the GFS structure 
corresponding to the extra 29 amino acids sequence in both DdahC and MlghC. Based on 
the structural alignment with GFS, both DdahC and MlghC have two domains, the co-
factor binding domain and the substrate binding domain. The co-factor binding domain 
was located by superimposing the structure with GFS/NADP+ co-crystal structure (Figure 
17-B). The residues that are predicted to catalyze or to bind the sugar ring in the binding 
site based on the functional analysis were highlighted (Figure 18). 
Based on structural modeling, the catalytic triad is conserved in location in 
DdahC compared to GFS, while in MlghC the tyrosine is substituted by phenylalanine 
(Figure 18) (Table 4). There is no adjacent tyrosine in the active site that could function 
as an alternative. However, Met110 was found close enough to form Ser106, Met110, 
and Lys139 (SMK) catalytic triad that has been previously identified in a UDP-GlcNAc 
C6-dehydratase, C4-reductase, WpbM (Figure 18-B) (40). In WpbM, the methionine 
residue of the catalytic triad was shown to be essential for catalysis (40). In addition, a 
cysteine residue, C68 that could be important for catalysis was found hanging on a loop 
in close location to the active site in MlghC (Figure 18-B). 
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Figure 17: The tertiary and quaternary structure model for the reductases. A. 
Ribbon representation of the superimposed structure model for DdahC and MlghC. 
Showed as a dimer where (A) monomer in yellow and (B) monomer is in blue. N and C 
annotate the N and C termini respectively. The co-factor binding site in both monomers is 
indicated by a double arrow. B. Ribbon representation of GFS from E. coli in gray ribbon 
with the co-factor NADPH in orange spheres (PDB code 1BSV). DdahC and MlghC 
overall structure resemble GFS structure except the unstructured loops.
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Figure 18: The reductases binding site structure model compared to the binding site 
of GFS. Ribbon and stick representation of the residues that are predicted to be involved 
in catalysis or substrate binding A. DdahC model superimposed with NADPH molecule 
of GFS structure.  B. MlghC model superimposed with NADPH molecule of GFS 
structure. C. GFS/NADPH co-crystal structure from E. coli (PDB code 1BSV). DdahC 
resembles GFS binding site more than MlghC.
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3.3.3. Site-directed mutagenesis: 
 For DdahC, four mutants were planned, three of which were generated by a 
previous lab member. T110C mutant was generated to mimic GFS activity. H180R and 
the double mutant H180R/T110Y mutants were generated to mimic MlghC activity. 
Several attempts made to generate the single T110Y mutant failed. However, it will be 
generated using reverse mutagenesis on the H180R/T110Y template to revert the mutated 
His180. For MlghC, only one mutant was planned and generated, C68A, to test the 
function of the cysteine in catalysis (Table 5). 
 
Table 5: SDM list for the reductases: 
Reductases Mutation Rational 
Rational of the 
substitution choice 
DdahC T110C 
Catalytic, testing 
specificity 
Mimic GFS catalysis 
 H180R 
Catalytic, testing 
specificity 
Mimic MlghC catalysis  H180R/T110Y 
 
T110Y* 
MlghC C68A 
Unknown 
function 
No functionality 
 
All mutations in this table were made by Michael Roubakha, 2013 
* Is to be generated. 
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3.4. Protein expression and purification: 
 The GDP-manno-heptose modifying enzymes, wild type and mutants, were 
successfully purified using affinity chromatography purification (Figure 19). The 
concentrations of the enzymes obtained by Bradford assay were optimized to have equal 
concentration of the wild type and mutants as shown in Figure 19-D. 
 
3.5. Epimerases enzymatic assays and kinetics: 
The enzymatic activity was tested for the wild-type and mutants of DdahB 
(N121S, H67A, and H67N) and MlghB (N121S, H67A, H67N, and Y134F) at the same 
enzymes concentrations following previously established conditions. The activity was 
tested on GDP-manno-heptose (kindly provided by Dr. Creuzenet) to see if the mutants 
fulfill their purpose of inactivating the enzyme if they are indeed catalytic residues. In 
addition, they were tested on GDP-mannose substrate, which is a hexose-based sugar 
nucleotide. Since our prediction for the residues’ function is based on the structural 
modeling and the comparison to enzymes that use hexose-based substrate, it is important 
to test the activity on such substrate. This analysis allows us to identify the residues that 
are specific to GDP-manno-heptose modification.  
 
3.5.1. Epimerases reactions on GDP-manno-heptose: 
The activity of DdahB and  MlghB wild type and the mutants was tested in three 
independent experiments  using  two different purified enzymes stocks. For the mean data 
of the three experiments’ integrations for DdahB and MlghB activity on GDP-manno-
heptose see Appendix 4. 
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Based on the in vitro pathway of GDP-manno-heptose modification, DdahB 
epimerizes P1 at C3 to generate one product, which is P4α (Figure 20-A1). The DdahB 
N121S mutant that was generated to investigate the function of the Asn in the substrate 
recognition and thus in the catalysis showed no significant difference compared to the 
wild type (Figure 21-A2). However, H67A and H67N mutants, which were predicted to 
be catalytically inactive had produced P4α, but significantly less than the wild-type (p < 
0.001) (Figure 21-A2). 
 On the other hand, MlghB is known to generate P4α, P4β, and P4γ by C3, C5, 
and C3/C5 epimerization respectively as observed for the MlghB wild type (Figure 21-
B1). There is an inter conversion between the substrate P1 and MlghB products toward 
P1 and P4γ. MlghB N121S mutant generated the same products with no significant 
difference to the wild type (Figure 21-B2). The histidine mutants of MlghB, H67A and 
H67N were unable to epimerize at C5 (no P4β or P4γ), but they could generate the C3-
epimer (P4α), although significantly less than the wild type (p < 0.001). The MlghB 
Y134F mutant that was predicted to be catalytically inactive produced all the three 
products, although significantly less P4α and P4β (p < 0.001 and p <0.01), respectively. 
The kinetics of DdahB and MlghB were measured for the wild type and the 
mutants for four time points. Due to the high efficiency of the enzymes, most of the 
products were at their maximum production yield in 5 minutes with no further changes at 
later time points (Figure 22). This experiment is to be repeated using lower enzymes 
concentration to highlight the differences between the wild type and the mutants’ 
kinetics. Nevertheless, the results were interpreted from the currently available data set 
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represented in Figure 22 with regards to differences in maximum product formation. For 
DdahB C3-epimerization (P4α), N121S mutant seemed to have no significant difference 
compared with the wild type (Figure 22-A). Both His67 mutants were significantly less 
active. For MlghB C3-epimerization (P4α production), N121S mutant was 10% less 
active than the wild type during the 20 min (Figure 22-B). Bothe MlghB His67 mutants, 
as well as Y134F were significantly less active than the wild type. For MlghB C5 and 
C3/C5-epimerization (P4β and P4γ production), N121S mutant was comparable to the 
wild type. The Y134F mutant was almost inactive and was very slow. No P4β or P4γ 
were detected for the His67 mutants.
91 
 
 
 
 
 
 
 
  
Figure 19: SDS-PAGE analysis of the purified GDP-manno-heptose modifying 
enzymes. A. Purified GDP-manno-heptose modifying enzymes. From 1 to 5 showing, 
DdahB (22 kDa), MlghB (22 kDa), DdahC (40 kDa), MlghC (41 kDa), and DdahA (40 
kDa) respectively. B. An example of the affinity chromatography purification of the 
His-tagged proteins. C. Purification of the GST-tagged HP0044 (73 kDa) by GSTrap 
FF column. D. Optimized concentrations for the epimerases and reductases. All gels 
were stained with Coomassie blue. 
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Figure 20:  In vitro experimental pathways for GDP-manno-heptose and GDP-
mannose modification. A. GDP-manno-heptose is dehydrated by DdahA generating P1. 
DdahB epimerizes P1 at C3 to generate P4α in equilibrium. MlghB epimerizes P1 at C3 
giving P4α, at C5 giving P4β, and at both C3 and C5 giving P4γ. The two directions 
arrows indicate interconversion in MlghB reaction preferably towered P1 and P4γ. 
DdahC reduces P4α at C4 to generate P5α. MlghC reduces P4γ at C4 to generate P5γ. B. 
GDP-mannose is dehydrated by HP0044 to generate P1’. MlghB generates P4’ in 
equilibrium by epimerization at unknown location. DdahC produces two products, PII 
and PIII, from P1’ or P4’. MlghC produces only PI from either P1’ or P4’.
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Figure 21: CE electropherograms and peaks percentage areas highlighting the 
activity of the epimerases, wild type and mutants, on GDP-manno-heptose.  The 
electeropherograms are example of one of the experimental repeats. For both panels (A1 
and B1), a base reaction (trace b) containing 0.17 mM P1 was prepared by incubating the 
GDP-manno-heptose (trace a) with 1.5 µmol DdahA and 0.13 mM NADP+ as an internal 
standard. A1. The activity of 1.0 pmol DdahB wild-type and mutants on P1 for 30 
minutes. B1. The activity of 1.0 pmol MlghB wild-type and mutants on P1 for 30 
minutes. The specific products are highlighted in bold. * denotes a small impurity present 
in the heptose preparation. Illustrative cartoon for the experimental pathway in the grey 
box. Panels (A2 and B2) shows the peaks percentage areas of DdahB and MlghB 
products for three independent experiments. * indicates (p < 0.01) and ** indicates  
(p < 0.001). Statistics were done using T-test. 
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Figure 22: Kinetics of the wild type epimerases and mutants’ activity on GDP-
manno-heptose. The graphs represent the percentage area of the product to the total area 
per reaction (Y-axis) for four time points over 20 minutes (X-axis) A. DdahB C3-
epimerization (P4α). B. MlghB C3-epimerization (P4α). C. MlghB C5-epimerization 
(P4β). D. MlghB C3/C5-epimerization (P4γ). Each reaction contains 0.17mM substrate 
and 1.0 pmol enzyme.  After Incubation, the samples were snap frozen in dry ice/ethanol 
at each time point and analyzed by CE. (Preliminary experiment). To be repeated with 
lower enzymes concentration to avoid the equilibrium at the first time point. 
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3.5.2. Epimerases reactions on GDP-mannose: 
It was established previously in our lab that the GDP-manno-heptose modifying 
enzymes act less efficiently on GDP-mannose substrate than on GDP-manno-heptose 
(111). DdahA that was used as the dehydratase to generate the 4-keto substrate for the 
epimerases from GDP-manno-heptose has a very poor activity on GDP-mannose, as 
longer incubation and higher enzyme concentration is needed to generate the 4-keto 
product (110). Therefore, HP0044, a GDP-mannose dehydratase from Helicobacter 
pylori, was used due to its high efficiency in the formation of P1’ (31). Based on the 
preliminary pathway for GDP-mannose, MlghB and DdahB can generate one single and 
identical product (P4’) but with different efficiencies (Figure 20-B). MlghB formation of 
P4’ is in equilibrium with P1’. P4’ could be an epimerized product, but the epimerization 
status and location onto P4’ are unknown. Two hypotheses can be proposed. The first 
hypothesis is that P4’ is a C3 epimer, because both MlghB and DdahB can perform C3-
epimerization, thus generating the same product. However, the single C3-epimerization is 
only proven for the heptose substrate, and MlghB and DdahB could function differently 
on a hexose-based substrate. The second hypothesis is that P4’ could be a double epimer, 
similar to RmlC, which releases a single product, a C3/C5 epimer from a hexose-based 
substrate. However, this requires both DdahB and MlghB to perform C3/C5 
epimerization. Unfortunately, P4’ cannot be identified by mass spectrometry because of 
its unstable nature as a 4-keto sugar.  
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In this analysis, the activity of the DdahB and MlghB wild type and mutant are 
tested on P1’ that is the dehydrated form of GDP-mannose in two independent 
experiments using two different purified enzymes stocks. For the mean data of the two 
experiments’ integrations for DdahB and MlghB activity on GDP-mannose see 
(Appendix 5). GDP-mannose was incubated with HP0044 to generate P1’ as well as 
either DdahB or MlghB wild type or mutants. MlghB reactions are incubated for one 
hour.  The results showed that MlghB N121S mutant generated the same product as the 
wild type with no significant difference (Figure 23-B1,B2). However, H67A and H67N 
were catalytically inactive. Y134F mutant was significantly less active than the wild-
type, but generated the same P4’(p < 0.01) (Figure 23-B2).  
The kinetics showed that at later time points, the N121S mutant produced slightly 
more P4’ than the wild-type, and the Y134F mutant produced almost the same amount of 
P4’ as the wild type but in a slower manner (Figure 24-A). The product degradation was 
measured during the kinetics and showed equal degradation in the wild type and the 
mutants’ reactions (Figure 24-B). This indicates that the differences in P4’ formation 
between the wild type and the mutants was due to the mutation rather than the 
degradation of the substrate. After 5 hours, 50% of the substrate was degraded. The 
activity of the wild type MlghB on GDP-mannose substrate was slower and less efficient 
than its activity on GDP-manno-heptose, which suggests that MlghB possesses 
specificity toward GDP-manno-heptose. 
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 The activity of DdahB was tested with five times the enzyme concentration and 
five times longer incubation time (5 hours) compared to MlghB. The wild-type had very 
little activity, and activity was almost undetectable for the DdahB mutants (Figure 23-A). 
No kinetics was performed for DdahB on GDP-mannose due to the insufficient product 
formation and the high substrate degradation observed over time. In contrast to the 
efficient activity of DdahB on GDP-manno-heptose substrate, DdahB had undetectable 
activity on GDP-mannose even at higher enzyme concentration. This difference indicates 
that DdahB has specificity to GDP-manno-heptose rather than GDP-mannose. 
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Figure 23: CE electropherograms and peaks percentage areas highlighting the 
activity of the epimerases, wild type and mutants, on GDP-mannose. The condition 
of the reactions and incubation times are different between DdahB and MlghB. A. The 
activity of 5.0 pmol of the wild type DdahB and the mutants on P1’ after 5 hours 
incubation at 37°C. To generate P1’, a base reaction containing 0.77mM GDP-mannose, 
2.0 pmol HP0044, and 0.1 mM NADP+ was incubated at 37°C for 90 minutes (trace a). 
B1. The activity of 1.0 pmol of the wild type MlghB and the mutants on P1’ after one 
hour incubation at 37°C. To generate P1’, a base reaction containing 0.77mM GDP-
mannose, 2.0 pmol HP0044, and 0.5 mM NADP+ was incubated at 37°C for 90 minutes. 
NADP+ was used as an internal standard. Illustrative cartoon for the experimental 
pathway in the grey box. B2. Shows the peaks percentage areas of MlghB products for 
two independent experiments. * indicates (p < 0.01) and ** indicates (p ≤ 0.001). 
Statistics were done using T-test. 
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Figure 24: Kinetics of MlghB wild type and mutants’ activity on GDP-mannose. The 
graph represents the percentage area of the product to the total area per reaction (Y-axis) 
for four time points over 20 minutes (X-axis). Each reaction contains 0.4mM substrate 
and 1.0 pmol enzyme.  After Incubation, the samples were snap frozen in dry ice/ethanol 
at each time point and analyzed by CE. A. The kinetics of P4’ formation by the wild type 
MlghB and the mutants. B. The degradation of the substrate over time (P2). The substrate 
was equally degraded in the wild type and the mutants’ reaction to 50% at the end of the 
kinetics. (Preliminary experiment). To be repeated to confirm the kinetics differences 
detected between the wild type and the mutants.
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3.6. Reductases enzymatic assays and kinetics: 
The activity and the substrate specificity of the reductases were tested for DdahC 
(T110C, H180R, and H180R/T110Y) and MlghC (C68A) compared to the wild type on 
heptose or mannose-based substrates. The epimerized products of the dehydrated GDP-
manno-heptose, P4α, P4β, and P4γ, were used as substrates to test the specificity of the 
mutated reductases. On the other hand, both the dehydrated (P1’) and the epimerized 
(P4’) forms of GDP-mannose were used as substrates to test the activity and product 
formation of the wild type. This analysis was performed to test the involvement of the 
mutated residues in either the activity or the substrate specificity of the reductases. It was 
also done to determine if the reductases would function differently on a mannose-based 
substrate rather than their heptose substrate. 
 
3.6.1. Reductases reactions on GDP-manno-heptose: 
The epimerized products of the GDP-6-deoxy-D-altro-heptose, P4α, P4β, and 
P4γ, were generated using MlghB, which can generate them in equilibrium, to test the 
activity and the substrate specificity of the reductases mutants. The activity and the 
substrate specificity of DdahC and MlghC have been established previously (111). 
Although they were predicted as C3/C5-epimerases, C4 reductases, they only perform 
NADPH-dependent reduction of their epimerized substrates at C4 generating different 
products. DdahC reduces the C3-epimer (P4α) into P5α, which is the end product of 
GDP-manno-heptose modification pathway in C. jejuni 81-176. MlghC reduces the 
C3/C5-epimer (P4γ) to generate P5γ.  
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The general activity of DdahC and MlghC mutants was tested in two independent 
experments. For data integration see Appendix 6. No statistics were done for the 
reductases activity on GDP-manno-heptose because no repeats were done for each of  the 
two experiments because the experimental conditions were different. The first experment 
was done using a reaction where MlghB was still available in the mix to continuously 
generate the three epimerized substrates throughout the reaction. The activity was 
interpreted from the formation of the reduced product, and the conversion of NADPH 
into NADP+. DdahC mutants, T110C generated 50% more P5α than the wild type with 
total conversion of NADPH. H180R mutant  had the same production of P5α as the wild 
type (Figure 25-A). However, the double mutant H180R/T110Y was catalytically 
inactive. On the other hand, MlghC C68A had 10%  lower activity than the wild type in 
the formation of P5γ with total conversion of NADPH into NADP+ (Figure 25-A). 
Despite the differences in the activity, the active mutants were able to generate the 
specific product just like the wild type, indicating that there is no change in the specificity 
of the products formed. However, the substrate specificity cannot be interpreted from this 
experiment set because all the substrates are being resupplied from P1 by MlghB that was 
still in the reaction. 
The second experiment was done using a reaction where MlghB was ultrafiltered 
after the generation of the three epimerized substrates, P4α, P4β, and P4γ to test the 
reductases mutants’ substrate specificity. The T110C mutant of DdahC showed more P5α 
formation than the wild type with an increase in NADP+ (Figure 25-B). H180R showed 
slightly less activity than the wild type. H180R/T110Y was catalytically inactive. 
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Changes in P4α were undetectable compared to the MlghB control reaction (Figure 25-B, 
trace a). Unfortunately, the MlghB control trace was obtained from an aliquot withdrawn 
before the ultrafiltration, which results in further interconversion of P4α into P1 as shown 
by the integration. Therefore, we could not interpret differences in the substrate 
utilization by the reductases by using MlghB reaction as a control. However, we used the 
inactive mutant H180R/T110Y reaction as a virtual control. A slight decrease in P4α was 
observed in the wild type DdahC and the active mutants, while a corresponding increase 
in P5α was observed. More decrease in P4α level was observed for T110C mutants as a 
result of the formation of more P5α. No change was observed in P4γ for all DdahC 
mutants. P4β was undetectable because it usually migrates with NADP+. For MlghC, the 
C68A mutant was less active than the wild type and showed the same substrate 
specificity as the wild type. A decrease in P4γ upon formation of P5γ was observed for 
MlghC wild type and C68A mutant, indicating that there is no change in the substrate 
specificity for the mutant. 
The kinetics of the wild type DdahC and MlghC were performed in the same way 
where MlghB was ultrafiltered from the reaction before adding the reductases. The 
results are interpreted as percentage of the products area to the total area of the product 
and substrate (Figure 26). With regards to the activity of DdahC and MlghC mutants, the 
results confirmed that T110C mutant was two times more active than the wild type, while 
H180R showed no difference. The double mutant H180R/T110Y was inactive even with 
longer incubations (Figure 26-A). The kinetics showed that the gradual increase in P5α 
formation is related to a gradual reduction in P4α, meaning that there was no change in 
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the substrate specificity of DdahC mutants. On the other hand, MlghC C68A mutant had 
comparable activity to the wild type at early time points but less activity after an hour of 
incubation with no change substrate specificity (Figure 26-B). 
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Figure 25: CE electropherograms highlighting the activity of the reductases, wild 
type and mutants, on GDP-manno-heptose.  A. The reductases activity in the presence 
of MlghB which can continuously supply P4α, P4β, and P4γ to the reductases as long as 
the P1 substrate is available. This allows testing the level of the activity of the wild type 
and the mutants. P4β was very difficult to resolve, as it often co-migrates with NADP+. A 
base reaction containing the three epimerized substrates (P4α, P4β, and P4γ) was 
generated to test the activity and the specificity of the reductases by incubating MlghB 
with 0.17 mM of freshly synthesized P1 out of GDP-manno-heptose (trace a) and 0.5mM 
NADPH. To that, 1.0 pmol of either DdahC and MlghC wild type or mutants was added 
and incubated for 30 minutes. DdahC reduces P4α into P5α, while MlghC reduces P4γ 
into P5γ. B. The reductases activity on fixed amounts of the preformed P4α, P4β, and P4γ 
substrate. This was done to facilitate determination of the substrate specificity of the 
mutants. A base reaction was set up using MlghB and 0.37 mM of freshly synthesized P1 
to generate the three epimerized substrates (Trace a). It also contained 0.5mM NADPH. 
This reaction was ultrafiltered (red dash line) to remove MlghB. Either DdahC or MlghC, 
wild type or mutants, was added to the filtrate and incubated for 30 minutes. The specific 
products are highlighted in bold. There is no change in the specificity of the mutants. * 
denotes a small impurity in the NADPH or the GDP-manno-heptose stocks. Illustrative 
cartoon for the experimental pathway in the grey box. See Appendix 6 for peaks 
integrations. 
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Figure 26: Kinetics of the reductases wild type and mutants on GDP-manno-
heptose. The graphs represent the percentage area of the reduced product to the total area 
of the substrate and the product per reaction (Y-axis), for seven time points over an hour 
(X-axis). A. DdahC C4 reduction of P4α. B. MlghC C4 reduction of P4γ. A base reaction 
containing 0.5mM NADPH and 0.37 mM of freshly synthesized P1 was incubated with 
MlghB to generate the epimerized substrates. This reaction was ultrafiltered to remove 
MlghB. Then it was equally divided in aliquots to which 0.5 pmol of each reductase was 
added. After incubation, the samples were snap frozen in dry ice/ethanol at each time 
point and analyzed by CE. (Preliminary experiment).   
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3.6.2. Reductases reactions on GDP-mannose: 
Preliminary data from our lab of the activity of DdahC and MlghC on GDP-
mannose substrate showed that they can use P4’, which is suspected to be epimerized, to 
generate different products. Two products were identified for DdahC, PII and PIII, while 
one product was observed for MlghC, PI. The nature of the theses products whether 
epimerized or reduced is unknown. In this analysis both the dehydrated (P1’) and the 
epimerized (P4’) forms of GDP-mannose were used as substrates to test the activity and 
the products formed by the wild type.  
There are two major limitations of this analysis. The first is, because the heptose 
modifying enzymes, DdahC and MlghC, are less efficient on such substrates, longer 
incubation is needed to reach detectable levels of the products. However, both substrates, 
P1’ and P4’, are 4-keto sugar nucleotides, and they degrade rapidly during long 
incubations. Therefore, very small amounts of DdahC and MlghC products can be 
detected above the baseline. The second is that DdahC and MlghC products migrate 
closely to the substrate in the CE analysis. DdahC PIII migrates as a left shoulder peak to 
the substrate P1’. DdahC’s PII migrate as a right shoulder peak to GDP-mannose, while 
MlghC’s PI migrates as a left shoulder to GDP-mannose. This close migration of the 
products to the substrates limits the measurement of the products formed. Therefore, it is 
difficult to interpret the differences between the wild type and the mutants. An efficient 
HP0044 enzyme should be used to completely convert GDP-mannose into P1’ to avoid 
any overlap between peaks and any confusion in peak assignments.  
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The first set of DdahC and MlghC wild type enzyme analysis was performed on 
both P1’ and P4’ (Figure 27). One part of this set was performed where GDP-mannose 
was incubated with HP0044 and MlghB, to generate P1’ and P4’, as well as each of 
DdahC or MlghC. MlghB reaction is an equilibrium reaction, meaning that it can 
constantly make P4’ out of P1’ as long as P1’ is available. Upon incubation with the wild 
type reductases, DdahC generates PII and PIII, while MlghC generates PI (Figure 27-
A1). The co-injection of DdahC and MlghC reactions confirms that these products are 
different (Figure 27-A2). Despite the fact that P4’ is assumed to be used by the 
reductases, there were detectable levels of P4’ substrate in DdahC and more in MlghC 
reactions. This could be from the activity of MlghB that continuously regenerates P4’ 
from P1’. P1’ can also be regenerated from GDP-mannose by the activity of HP0044 that 
was also available in the reaction, which explain the disappearance of GDP-mannose 
peak in both DdahC and MlghC reactions (Figure 27-A1). The second part is performed 
where both HP0044 and MlghB were sequentially removed from the reaction after the 
generation of their products. The filtrate, containing P1’ and P4’ without the enzymes, 
was used to add either DdahC or MlghC. Upon incubation with the reductases, both 
enzymes generate their specific products, PII and PIII for DdahC, and PI for MlghC, with 
total conversion of both P1’ and P4’. This indicates that DdahC and MlghC can use both 
P1’ and P4’. In addition, NADPH was totally converted into NADP+ (Figure 27-B). 
The second set of the analysis was to test if they can use P1’ by itself (Figure 28). 
GDP-mannose was incubated only with HP0044 to generate P1’. Upon incubation with 
DdahC and MlghC, both reductases were able to generate their specific products from 
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P1’ (Figure 28-A). For total conversion of GDP-mannose, HP0044 was incubated for two 
hours resulting in more degradation of P1’ and formation of an unknown peak. This 
unknown peak migrates similarly to P4’. To make sure that this unknown product was 
not used by the epimerases instead of P1’, a similar experiment set was performed using 
newly purified HP0044 to aid the total conversion of GDP-mannose in shorter incubation 
time. Using newly purified HP0044 was necessary as it seems that HP0044 loses some of 
its activity upon long storage. HP0044 was removed from the reaction after total 
conversion of the GDP-mannose, and DdahC or MlghC were added to the filtrate. Upon 
incubation, both DdahC and MlghC generate their specific products in the absence of the 
unknown peak (Figure 28-B). All P1’ was used by DdahC to generate PII and PIII, while 
some is left in MlghC reaction.  
The activity and product specificity of the mutants were tested on P1’ using the 
same conditions (Figure 29). Unlike the activity on heptose substrate, T110C mutant 
generates both products, PII and PIII, but less than the wild type. However, H180R 
mutant shows similar activity to the wild type generating PII and PIII. H180R/T110Y is 
catalytically active and shows less activity than the wild type. On the other hand, MlghC 
product peak is very small and close to the baseline. However, there is no difference 
between the wild type and C68A mutant (Figure 29).  
The kinetics of DdahC and MlghC wild type and mutants were performed where 
both MlghB and HP0044 were available in the reaction. The results interpreted for the 
percentage of the products area to the total area of all products and substrates, P1’ and 
P4’ (Figure 30). For DdahC’s PII product, T110C mutant is significantly slower than the 
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wild type, while H180R mutant was equivalent to the wild type in the early time points. 
At late time points, PII was undetectable for H180R mutant (Figure 30-A). The kinetics 
for H180R/T110Y was not performed at the time of this experiment. DdahC’s PIII 
kinetics was not included. PIII was undetectable at most of the time points because of the 
low resolution from the migration with the substrate P1’. On the other hand, MlghC’s PI 
product was also undetectable at early time points. C68A mutant was significantly slower 
than the wild type and generated less PI (Figure 30-B). 
3.7. Summary of the enzymatic assays and kinetics: 
The enzymatic activity and the kinetics results of GDP-manno-heptose wild type 
and mutated epimerases and reductases are summarized in Table 6. 
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Figure 27: CE electropherograms highlighting the activity of the reductases on the 
dehydrated and the epimerized product of GDP-mannose (P4’). A. DdahC and 
MlghC can generate their products either from the dehydrated form (P1’) or the 
epimerized form (P4’) of GDP-mannose (Trace c, d). A base reaction where GDP-
mannose was incubated with HP0044 and MlghB to generate both P1’ and P4’ in 
equilibrium was used to test the activity of the reductases. P1’ is degraded over time into 
P2. Incubation with DdahC generates two products (PII and PIII) (trace c), while 
incubation with 1.5 pmol of MlghC generates only one (PI) (trace d). However, left over 
substrates were observed. Because the products migrate close to each other and to the 
substrate, both reactions were co-injected to show that they are different (Trace e), 
zoomed out in the red box. * denotes a small impurity in the NADPH stock. B. Confirms 
that the reductases are using both P1’ and P4’ due to the disappearance of their 
corresponding peaks (trace b, c). No regeneration of P1’ and P4’ was observed because 
both HP0044 and MlghB were ultrafiltered from the reaction (red dash lines) before 
adding the reductases. Illustrative cartoon for the experimental pathway in the grey box. 
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Figure 28: CE electropherograms highlighting the activity of the reductases on the 
dehydrated product of GDP-mannose (P1’).  A. The activity of DdahC and MlghC on 
P1’ only. P1’ was synthesized from GDP-mannose by incubation with HP0044 for 2 
hours (trace b). P1’ is degraded over time into P2. After total conversion of GDP-
mannose into P1’, the reaction was divided and each of the reductases was added 
separately along with NADPH. Incubation with DdahC generates two products (PII and 
PIII) (trace c), while incubation with MlghC generates only one (PI) (trace d). Because 
the products migrate close to each other and to the substrate, both reactions were co-
injected to show that they are different (Trace e), zoomed out in the red box. * denotes a 
small impurity in the NADPH stock. # denoted an unknown product that results from 
long incubation of HP0044. B. The unknown product (#), shown in panel A is indeed 
from longer incubation of HP0044, and it is not used by the epimerases. After total 
conversion of GDP-mannose into P1’ by newly purified HP0044 in 60 minutes (trace a), 
the reaction was ultrafiltered to remove HP0044. This was divided and each of the 
reductases was added (trace b, c). No formation of the unknown product (#) and less 
degradation of P1’ is seen. Also, both DdahC and MlghC made their products using P1’. 
Illustrative cartoon for the experimental pathway in the grey box. 
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Figure 29: CE electropherograms highlighting the activity of the reductases wild 
type and mutants on the dehydrated product of GDP-mannose (P1’). The activity of 
the wild type DdahC and MlghC and the mutants on P1’. P1’ was synthesized from GDP-
mannose by incubation with HP0044 for 60 minutes (trace a), the reaction was 
ultrafiltered to remove HP0044. This was equally divided and each wild type or mutant 
was added separately. There was very little products formation due to an insufficient 
amount of the substrate. * denotes a small impurity in the NADPH stock. Illustrative 
cartoon for the experimental pathway in the grey box. 
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Figure 30: Kinetics of the reductases wild type and mutants’ activity on GDP-
mannose. P1’ and P41 were the substrates for this set. Representing the percentage area 
of the product to the total area of sugar nucleotides per reaction (Y-axis) for six time 
points over 95 minutes (X-axis). A. The formation of PII product of DdahC. B. The 
formation of PI product of MlghC.  
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Table 6: Summary of the enzymatic assays and kinetics of the mutants compared to 
the wild type epimerases and reductases. 
 
 Epimerases Mutation Rational 
On GDP-manno-
heptose 
substrates 
On GDP-
mannose 
substrates 
DdahB N121S* 
Substrate 
recognition 
(binds O4) 
No significant 
difference in P4α 
formation 
UD  H67A 
Catalytic, 
inactivate. 
significantly less 
P4α (p < 0.01) 
 H67N 
Catalytic, 
inactivate. 
significantly less 
P4α (p < 0.01) 
MlghB N121S* 
Substrate 
recognition 
(binds O4) 
No significant 
difference in P4α, 
P4β, or P4γ 
No significant 
difference in 
P4’ 
 H67A 
Catalytic, 
inactivate. 
No P4β or P4γ. 
And significantly 
less P4α  
(p < 0.001) 
Inactive 
 H67N 
Catalytic, 
inactivate. 
No P4β or P4γ. 
And significantly 
less P4α 
(p < 0.001) 
 Y134F 
Catalytic, 
inactivate. 
Significantly less  
P4α and P4β  
(p < 0.001 and < 
0.01), respectively 
Significantly 
less  P4’ 
(p < 0.01) 
120 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UD: undetectable. DdahB WT is not efficient on GDP-mannose substrate. 
C3, C5, C3, 5 indicate the epimerization sites.  
* Results listed based on the kinetics. The percentages of the differences in the activity 
are for the last time points (Figure 30). 
 
 
  
Reductases Mutation Rational 
On GDP-manno-
heptose 
substrates 
On GDP-
mannose 
substrates * 
DdahC T110C 
Catalytic, 
testing 
specificity 
No change in 
specificity.  
50% more P5α 
(faster) 
20% less PII 
(slower). 
 H180R Catalytic, 
testing 
specificity 
No change in 
specificity.  
P5α similar to WT  
PII is similar to 
WT.  
 
H180R/T
110Y 
Inactive Active 
MlghC C68A 
Unknown 
function 
No change in 
specificity. 
10% less P5γ 
(slower) 
70% less PI 
(slower) 
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3.8. Biofilm assay: 
The wild-type strain, C. jejuni NCTC11168, was tested for biofilm formation 
along with four heptose biosynthesis mutants and a capsule-less mutant that were 
generated previously in our lab: wcaG::cat, mlghC::cat, mlghB::cat,  wcaGΔ::cat, and 
kpsM::kan (184). The kpsM::kan, a capsule-less strain, was used as a negative control as 
the capsule was thought to have a role in biofilm formation (178). All the other mutants 
have intact capsule except that it is devoid of the methylated heptose that is found in the 
wild type (184). The wcaGΔ::cat mutant has deletions of the precursor GDP-manno-
heptose synthesis genes (cj1423c- cj1425c), the heptose methyl transferase gene 
(cj1426c), and other capsule MeOPN transferases genes (cj1421c and cj1422c). 
Therefore, wcaGΔ::cat mutant contains the capsule backbone with no modifications, no 
heptose, no methylation, and no MeOPN (184). The formation of biofilm by the wild 
type and the mutants was measured every day for four days after an initial incubation. 
The biofilm formation was tested under aerobic conditions, which are more relevant for 
the survival of the organism in the environment. It has been shown that C. jejuni’s 
biofilm formation increases under aerobic conditions (146). Perhaps it helps to minimize 
the oxygen concentration for survival.  The biofilm formation was also tested under 
microaerobic conditions, which are the favorable conditions for C. jejuni growth. This 
was done to confirm that the wild type C. jejuni does not need to make more biofilm 
under microaerobic conditions. Also to investigate whether lacking the modified heptoses 
would stress the bacterial cells and drive them to make more biofilm than the wild type 
under microaerobic conditions. 
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 Under aerobic conditions, the wild type C. jejuni NCTC11168 made significantly 
more biofilm than the negative control, kpsM::kan strain, at all detection days (p< 0.001) 
(Figure 31). In addition, the amount of C. jejuni NCTC11168 biofilm has increased 
significantly at the last day compared to the first day (p< 0.001) (Figure 31). 
Comparing the biofilms formed by the mutants to the wild type at each detection 
day showed that the wcaG::cat mutant had significant reduction in the biofilm amount at 
the first day (p< 0.004), as well as at the following days (p< 0.001). The wcaG::cat 
mutant made significantly more biofilm at the last day of detection compared to the first 
day (p< 0.001). The mlghC::cat mutant’s biofilm was significantly less than the wild 
type at all detection days (p< 0.001), and comparable to the negative control kpsM::kan at 
the first three days. There was an increase in biofilm in the last day compared to the first 
day of detection (p< 0.002). The mlghB::cat mutant’s biofilm was also significantly less 
than the wild type (p< 0.001), and comparable to the negative cotrol kpsM::kan at all 
detection days. No difference was observed in the biofilm between the first and the last 
days of detection. The wcaGΔ::cat mutant had significantly less biofilm than the wild 
type at all days of detection (p< 0.001). The biofilm of wcaGΔ::cat mutant was 
comparable to the negative control at the first two days of detection. There was a 
significant increase in the wcaGΔ::cat mutant’s biofilm amount at the last day compared 
to the first day of detection (p< 0.001) (Figure 31). 
In microaerobic condition, C. jejuni NCTC11168 wild type was able to make 
significantly more biofilm than the negative control, kpsM::kan strain (p< 0.001) (Figure 
32). The biofilm formed at all days of detection did not change. These results suggest that 
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C. jejuni NCTC11168’s biofilm is indeed increasing under aerobic condition, but not 
under microaerobic conditions. 
The wcaG::cat mutant has significantly less biofilm than the wild type at the first 
two days of detection (p< 0.001). However, the amount of biofilm at the last two days of 
detection was comparable to the wild type. The difference between the first and the last 
day of detection of wcaG::cat mutant’s biofilm was significant (p< 0.001), meaning that 
unlike the wild type, wcaG::cat mutant’s biofilm was increasing.  
There was no significant difference between the mlghC::cat mutant’s biofilm 
amount and the wild type at all detection days, except at the second day where it was 
significantly higher than the wild type (p< 0.001). The ammount of mlghC::cat mutant’s 
biofilm at the first and the last day of detection was decreased (p= 0.004). Compared to 
the increasing biofilm formed under the aerobic condition, mlghC::cat mutant behave 
differently. It decreased under microaerobic condition, but increased under aerobic 
condition. 
 There is no significant difference between mlghB::cat mutant and the wild type 
biofilm amount at all detection days. The mlghB::cat mutant has no significant difference 
between all days of detection. Compared to the aerobic biofilm, mlghB::cat mutant was 
better at making biofilm under microaerobic rather under aerobic conditions, yet the 
biofilm amount is not changing over days of incubation at both conditions. 
Finally, the wcaGΔ::cat mutant’s biofilm amount was significantly less than the wild 
type and comparable to the negative control at the first two days of detection. At the last 
day of detection, the wcaGΔ::cat mutant’s biofilm amount had significantly increased 
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compared to the first day of detection (p< 0.001) (Figure 32). Compared to the increased 
biofilm formation under the aerobic condition, wcaG∆::cat mutant biofilm had increased 
similarly under microaerobic condition. 
The bacterial cell inoculums that were used in both experiments for each mutant 
were analyzed for the quality of the capsule by SDS-PAGE using Hitchcock and Brown 
method. After silver-staining, the SDS-PAGE showed that all the mutants, except the 
capsule-less kpsM::kan mutant, have the capsule patterns that are found in the wild type 
(Figure 33). The presence of the capsule in the heptose biosynthesis mutants indicates 
that the differences in biofilm formation compared to the wild could be related to the lack 
of the modified heptose in the capsule.  
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Figure 31: Biofilm formation by C. jejuni NCTC 11168 wild type, as well as the 
capsule and the heptose biosynthesis mutants under aerobic conditions. Biofilm 
formation was measured every day for four days after the initial incubation under aerobic 
conditions. Different letters indicate significant difference at (P≤0.001). Two letters 
indicate no significance difference with either letters. Statistics were done using one-way 
ANOVA test 
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Figure 32: Biofilm formation by C. jejuni NCTC 11168 wild type, as well as the 
capsule and the heptose biosynthesis mutants under microaerobic conditions. 
Biofilm formation was measured every day for four days after the initial incubation under 
microaerobic conditions. Different letters indicate significant difference at (P≤0.001). 
Two letters indicate no significance difference with either letters. Statistics were done 
using one-way ANOVA test. 
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Figure 33: SDS-PAGE analysis of the capsule content of C. jejuni NCTC 11168 wild 
type, as well as the capsule and the heptose biosynthesis mutants. The capsule (CPS) 
and the lipooligosaccharide (LOS) fractions of cells samples prepared by Hitchcock and 
Brown method. The gel was visualized by silver staining. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
CHAPTER 4 - DISCUSSION
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4.1. The substrates and products specificity of the epimerases: 
DdahB and MlghB have specificity toward GDP-manno-heptose rather than 
GDP-mannose substrate. DdahB epimerizes GDP-6-deoxy-4-keto-D-lyxo-heptose, P1, 
only at C3 generating P4α, while MlghB epimerizes P1 as a surrogate substrate at C3, 
C5, and both carbons generating three epimerized products, P4α, P4β, and P4γ. On the 
other hand, using the dehydrated GDP-mannose substrate (P1’) to investigate the 
specificity of the active site showed that DdahB and MlghB generate a single product of 
unknown epimerization status (P4’), yet both are less efficiently active compared to the 
activity on GDP-manno-heptose substrate. DdahB is even less efficient than MlghB, as it 
failed to generate detectable products at higher enzyme concentration and longer 
incubation time. The epimerization status of P4’ is unknown. To address what epimer P4’ 
is, P4’ should be identified using mass spectrometry combined with deuterium 
incorporation analysis as done previously to characterize the heptose epimers in our lab 
(112). However, this approach is not feasible due to the instability of P4’ and the 
insufficient amounts that can be generated. 
 
4.2. Substrate binding and catalytic site of the epimerases: 
The binding of the enzyme to the substrate is dominated by the nucleotide portion. 
Therefore, the nucleotide binding determines the conformation that the ligand will adopt 
in the enzyme active site (46). The dTDP-phenol adopts a U shape in RmlC rather than 
extended conformation (34, 55). Whether there is a difference between dTDP and GDP 
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nucleotides in term of the conformation of  binding to the enzyme cannot be derived from 
the data we have. However, the MlghB/GDP-mannose co-crystallography, although the 
mannose ring was not included in the final figure, showed that the ligand could be fitting 
in a U-shape in the binding site (Figure 15). The guanidine ring of the GDP moiety is 
found between the N-terminus Met1 of the B subunit, Ile32, and Lys54 residues. Phe24 is 
stacking against the ribose ring of the GDP. Other residues were identified that belong to 
a loop that was unstructured in the non-bound MlghB (Figure 15). Upon GDP-mannose 
binding, this loop, containing Tyr142 and Asp144, was shown to make a pocket for the 
GDP moiety. This loop could be important in regulating the substrate/product route into 
and out of the active site as observed  in RmlC enzymes (34, 55, 60).  
Based on the comparative functional analysis, the modeling and the 
crystallography structures, as well as the mutagenesis, some of the functional residues 
that are involved in the catalysis are identified in DdahB and MlghB. 
The Asn121 residue is predicted to be important for binding the 4-keto group of 
the substrate through the amide. This binding will lower the pKa value of the protons 
attached to C3 and C5 to facilitate the deprotonation (4). Asn121 was mutated into serine 
in DdahB and MlghB to test its involvement in 4-keto group binding. Based on the 
enzymatic analysis, Asn121 is not essential for the catalysis of DdahB or MlghB on 
hexose or mannose-based substrates (Figure 21,23). However, Asn121 involvement in 
the substrate 4-keto binding cannot be interpreted by testing the current mutant, as the 
substitution into serine could be conserving the function by interacting with the 4-keto 
through the hydroxyl group. Another mutation where the Asn121 is mutated into a 
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residue with a non-polar side chain, such as alanine, can be proposed to test the Asn 
function. 
A histidine-aspartate catalytic diad is conserved among the hexose-based 
epimerases (RmlC) in many gram-negative bacteria (45, 63). It is important for C3 and 
C5 epimerization as found in S. enterica’s and S. suis’s RmlC. It has been shown that in 
such His-Asp diad, the aspartate role is to increase the basicity of the histidine to aid the 
catalysis. However, the histidine still could function in the absence of the aspartate 
although with less activity (45, 63). The His67-Asp173 diad was found in both DdahB 
and MlghB. However, based on the crystallography of DdahB, the Asp173 was away 
from the His67 and it was not conserved in the location compared to its location in 
MlghB (Figure 14). The difference in the structure could explain the inability of DdahB 
to function like MlghB under the same conditions to perform C5 epimerization. This can 
be further addressed by mutating the Asp173 in MlghB into a non-functional residue to 
see if MlghB will lose its C5 epimerization function.  
The His67 was predicted as the catalytic residue for C3 epimerization  in DdahB 
and it was mutated into asparagine or alanine. DdahB H67A and H67N were significantly 
less active than the wild type (Figure 21). The loss of activity indicates that the His67 is 
involved in C3 epimerization, yet there is another residue that can perform this function. 
In MlghB, the His67 was predicted to be catalytic for C3 and C5 epimerization. Mutating 
the His67 into alanine or asparagine resulted in complete loss of the epimerization 
function at C5. No C5-epimer (P4β) or C3/C5-epimer (P4γ) were detected even at longer 
incubations as shown by the kinetics. Nevertheless, both mutants, H67A and H67N were 
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poorly able to epimerize at C3 generating significantly less P4α than the wild type. These 
data indicate that His67 is the catalytic residue for MlghB’s C5 epimerization. Consistent 
with the His67 mutant’s analysis in DdahB, the slight C3 epimerization activity detected 
in MlghB His67 mutants indicates that His67 is involved in C3 epimerization, but there is 
another functional residue performing the epimerization at C3. 
On GDP-mannose, the hexose-based substrate, both H67A and H67N of MlghB 
were catalytically inactive, even at longer incubations as shown by the kinetics (Figure 
23). In RmlC, which utilizes a hexose-based substrate generating a single C3/C5-epimer, 
mutating the corresponding histidine resulted in inactivation of the enzyme. Therefore, it 
is possible that MlghB is functioning like RmlC when utilizing a hexose-based substrate 
by generating a single product. The loss of MlghB hexose-based product (P4’) upon 
mutating the histidine indicates that P4’ could be a C3/C5-epimer.  
   The Tyr134 was predicted as a catalytic residue for C3 and C5 epimerization 
and it was mutated into phenylalanine to test the function of the hydroxyl group in the 
catalysis. The data only showed the activity of MlghB Y134F but not DdahB Y134F, 
because the DdahB Y134F mutant was not generated at the onset of this experiment. 
Surprisingly, MlghB Y134F mutant was catalytically active. However it showed 
significantly less P4α  and P4β compared to the wild type (Figure 21). The fact that P4γ 
production was not affected could be explained by the preferable interconversion towered 
P4γ. The formation of all epimerized products indicates that Tyr134 is not essential for 
C3 or C5 epimerization.  
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On GDP-mannose substrate, MlghB Y134F mutant was significantly less active 
than the wild type (Figure 23). The  poor activity of MlghB Y134F indicate that the 
Tyr134 is not essential for catalysis. The structural modeling of the Y134F mutant 
suggested that the compensation for the mutated Tyr134 function in MlghB Y134F could 
be done by an adjacent Tyr132. A change in the orientation of Tyr134 was observed in 
Y134F model compared to the wild type (Figure 12). The same change was also observed 
in the N121S mutant, indicating that Y132 could have a flexible conformation of its side 
chain. To investigate whether Tyr132 is compensating for Tyr134 function in the 
catalysis of MlghB, or whether it is a catalytic residue, the single mutant Y132F, and the 
double mutant Y134F/Y132F were generated for DdahB and MlghB by an M.Sc 
candidate (Chelsea Kubinec). The activity of these mutants is under investigation. 
Another function is predicted for Tyr132 based on the structure of DdahB and 
MlghB. Tyr132 and His123 are aligned with conserved aromatic residues in RmlC 
enzymes, usually Phe/Phe pairs (Figure 11). Thus, Tyr132 and His123 could function in a 
stacking interaction with to physically stabilize the substrate during catalysis. 
The Lys74 was predicted as a catalytic residue for C3 epimerization. Based on 
the structure of DdahB and MlghB, Lys74 was the only residue that could function as a 
base on the upper face of the active site. Therefore, it could deprotonate the substrate at 
C3 from the upper face of the sugar ring. As shown in RmlC, the corresponding lysine 
was essential for C3 epimerization (45, 55). The mutation of Lys74 into alanine has been 
created for both DdahB and MlghB but the enzymatic activity of the mutated enzymes is 
under investigation. 
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The Gln85 was predicted to be involved in catalysis. Gln85 could not be directly 
involved in the epimerization because it is located at the end of the active site on the 
sugar-ring side (Figure 15-C). Nevertheless, it could be stabilizing an adjacent catalytic 
residue that is involved directly in catalysis. Gln85 may perhaps be interacting with the 
Asn121 through the amide group by a hydrogen bond (21, 63). 
In conclusion, the role of Asn121 in the 4-keto group recognition of DdahB’s and 
MlghB’s substrates is still unknown. In order to address that, mutating the Asn121 into a 
residue with non- polar side chain is needed. The His67 is the catalytic residue for MlghB 
C5 epimerization. The Asp173 is forming a diad with His67, and it could be essential for 
C5 epimerization in MlghB. DdahB Asp73 is not conserved in its location in the 
structure. Therefore, DdahB cannot perform C5 epimerization. His67, by itself, is 
involved in C3 epimerization of both MlghB and DdahB, but there is another residue 
performing C3 epimerization. Lys74 could be the catalytic residue for C3 epimerization 
based on the structure.  The Tyr134 is involved in C3 and C5 epimerization in MlghB, 
and C3 epimerization in DdahC, yet it is not essential. Tyr132 could be a catalytic 
residue, or it could compensate for the Tyr134 function in catalysis. Gln85 could be a 
secondary catalytic residue that is interacting with Asn121 to aid the catalysis. The co-
crystallography of DdahB and MlghB with their GDP-manno-heptose substrate will 
increase our understanding of the residues’ function in the active site.  
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4.3. The substrates and products specificity of the reductases: 
DdahC and MlghC are highly specific in their choice of the substrate and in their 
products formation. The specificity of DdahC and MlghC toward their substrate was 
investigated previously by providing the three epimerized substrates in the reaction (111). 
DdahC only reduces the C3 epimer (P4α) that is generated by DdahB at C4 in an 
NADPH-dependent manner to generate the final product GDP-6-deoxy-D-altro-heptose 
(P5α). DdahC can also use the same P4α that is generated by MlghB C3 epimerization 
generating the same product P5α. DdahC does not use the P4β or P4γ generated by 
MlghB. In vitro, MlghC reduces the double epimer (P4γ) that is generated by MlghB. 
The reduction occurs at C4 in an NADPH-dependent manner to generate GDP-6-deoxy- 
L-gluco-heptose (P5γ) (111).  
DdahC and MlghC also have specificity toward GDP-manno-heptose substrates 
rather than GDP-mannose substrates. Using dehydrated GDP-mannose substrate (P1’) 
and/or the epimerized form (P4’) to investigate the specificity of the reductases showed 
that both DdahC and MlghC are less efficient in utilizing these substrates compared to 
GDP-manno-heptose substrates. The analysis also showed that DdahC and MlghC can 
use both P4’ and/or P1’. By using each of these substrates, DdahC generates two 
products, PII and PIII, while MlghC generates one product, PI. The nature of these 
products whether reduced or epimerized is unknown. Because DdahC and MlghC possess 
the functional residues necessary for the epimerization, they could be functioning 
differently when utilizing a hexose-based substrate by performing an epimerization 
reaction. Unlike their activity in GDP-manno-heptose modification, where they only 
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reduce an epimerized substrate, they could be epimerizing the dehydrated GDP-mannose 
(P1’) then reducing it just like other hexose-based substrate C3/C5 epimerases, C4 
reductases, such as GFS.  The fact that the generated products for DdahC or MlghC from 
P1’ and P4’ are the same suggest that they could be reducing the newly epimerized 
P1’and the already epimerized P4’ into the same products. Unfortunately, it is difficult to 
identify the nature of these products by mass spectrometry coupled with deuterium 
incorporation due to their instability and the extremely low yields. 
 
4.4. Substrate binding and catalytic site of the reductases: 
DdahC and MlghC overall structure indicates that both are members of the SDR 
family (79). They have two domains, the co-factor binding domain and the substrate 
binding domain. The residues that bind the NADPH in the co-factor binding domain are 
found conserved with other SDR members and they were not discussed for simplicity. 
Based on sequence alignment and the modeling, a set of hydrophobic residues forming 
the binding pocket for GDP was identified (Table 4). Based on co-crystallography of 
GFS and its substrate, a tryptophan residue is functioning as a gate to the substrate 
binding site as it moves after binding to cover the substrate (99, 157). Therefore, the 
corresponding tryptophan in DdahC and MlghC could be functioning in a similar fashion. 
Based on the comparative functional analysis and the modeling, two residues 
were predicted to interact with the sugar ring, Asn166 and Thr109 in DdahC, Asn165 and 
Gly108 in MlghC, however, their role in catalysis is unknown. The residues that catalyze 
the reduction activity of DdahC and MlghC have been identified. DdahC possesses the 
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SYK catalytic triad that found in GFS, Ser108, Tyr137, and Lys141, while MlghC 
possesses SMK catalytic triad, Ser106, Met110, and Lys139, similar to what has been 
identified in a UDP-GlcNAc C4,6-dehydratase, WpbM (39, 40, 99). On the other hand, 
aligned with the residues that were predicted to catalyze epimerization activity in GFS, 
Cys109 and His170, DdahC had His180 and Thr110, while MlghC had Arg181 and 
Tyr109. In this study, the residues His180 and Thr110 in DdahC have been targeted for 
mutagenesis studies for two reasons. The first is that DdahC and MlghC are known to 
perform NADPH-dependent reduction but not epimerization reactions. The second is that 
theses residues are not conserved in both enzymes, which suggest their involvement in 
the substrate and/or the product specificity.  
The Thr110 was mutated into cysteine to mimic GFS catalysis by performing an 
epimerization activity or by reducing a double epimer. The DdahC T110C mutant did not 
change its substrate and it generated the same product as the wild type, P5α, although it 
was faster and generated 50% more P5α than the wild type (Figure 25). This indicates 
that Thr110 is not involved in the substrate or the product specificity on GDP-manno-
heptose. The cysteine in DdahC T110C could have reduction potential resulted in 
increasing the activity of DdahC. 
Based on the available data for the activity on GDP-mannose, DdahC T110C 
mutant was slower than the wild type (Figure 30-A) (Figure 26-A). The differences in the 
catalysis rate of DdahC T110C on GDP-manno-heptose versus the activity on GDP-
mannose indicate that Thr110 confers specificity to the substrate whether heptose-based 
or hexose-based substrate 
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The His180 was mutated into arginine in DdahC to mimic MlghC’s substrate 
specificity by reducing the double epimer P4γ. However, the DdahC H180R mutant did 
not change its substrate, which is the C3-epimer P4α, and it generated the same product 
as the wild type in a similar amount (Figure 25). On GDP-mannose, the DdahC H180R 
mutant showed similar activity to the wild type. His180 perhaps is not important for the 
substrate specificity or the reduction activity of DdahC. However, it is possible that 
mutating the His180 into arginine does not affect the function simply because both the 
histidine and the arginine have nitrogen on their side chain. 
The double mutant H180R/T110Y that was generated to mimic MlghC’s 
reduction of P4γ was catalytically inactive (Figure 25). Because the single H180R mutant 
was active and comparable to the wild type, the mutation of the Thr110 into tyrosine 
could be the reason of inactivation. When Thr110 was mutated into cysteine, DdahC 
gained catalytic efficiency, while when Thr110 was mutated into tyrosine DdahC lost its 
function. This suggests that Thr110 is a critical amino acid for DdahC activity. The 
choice of a substitution to Thr110 is very important and is affecting the activity 
differently. The exact role of the Thr110 in DdahC cannot be identified based on these 
substitutions as they were chosen to mimic the catalysis of other enzymes. To address if 
Thr110 has a role in the reduction activity of DdahC, Thr110 needs to be substituted with 
a residue with a non-functional side chain. 
On GDP-mannose, the double mutant DdahC H180R/T110Y was unexpectedly 
active, and it generated the same products as the wild type (Figure 29). This surprising 
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finding suggests that if Thr110 has a role in catalysis, its function is specific for utilizing 
GDP-manno-heptose substrates rather than GDP-mannose. 
 The Cys68 in MlghC was mutated into alanine to test its involvement in the 
activity of MlghC. C68A mutant generated the same product as the wild type, but 10% 
less. C68A mutant was slower than the wild type, and the product formation was 50% 
less than the wild type at longer incubation (Figure 30). This suggests that Cys68 is 
involved in promoting the catalysis rate, perhaps by binding to the co-factor or its 
reduced form. Based on the modeling Cys68 is close enough to interact with the 
nicotinamide ring of the co-factor. 
In conclusion, testing the Thr110 and the His180 residues of DdahC showed that 
these residues are not involved in the specificity toward the epimerized substrates of 
GDP-manno-heptose. Nevertheless, Thr110 could be an important residue for DdahC 
activity. The function of Thr110 needs to be further investigated regarding its 
involvement in DdahC reduction activity. The choice of the substitution amino acid for 
Thr110 has a significant impact on the activity of DdahC. Mutating the Thr110 into 
cysteine resulted in an increase in the substrate utilization and catalysis rate on the 
heptose-based substrate. However the same mutation resulted in a decrease in the 
catalysis rate on a hexose-based-substrate. The type of the function performed by DdahC 
T110C mutant whether an epimerization, a reduction, or both still needs to be 
investigated. In MlghC, the Cys68 is involved in catalysis maybe by interaction with the 
co-factor. 
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To further investigate the active site specificity of DdahC and MlghC, the 
catalytic triad that is essential for the reduction activity needs to be targeted for 
mutagenesis. The difference in the catalytic triad in DdahB (SYK) versus MlghC (SMK) 
could be related to the substrate and/or the product specificity. 
 
4.5. The involvement of the modified heptose of C. jejuni NCTC 11168 in biofilm 
formation. 
The role of the modified heptoses with regards to bacterial resistance to serum 
and bile salt, adhesion and invasion to host cells, as well as chicken colonization has been 
investigated in C. jejuni NCTC 11168  (184). The wild type C. jejuni NCTC 11168 and 
the heptose biosynthesis mutants are perfect tools to test the involvement of the modified 
heptoses in C. jejuni virulence in vitro for two reasons.The first is that C. jejuni NCTC 
11168 possesses the modified heptose as a side branch of the CPS backbone. The 
location of the modified heptose as a side branch makes it the outermost exposed 
structure to the extracellular environment, thus suggesting the possible interaction of the 
modified heptose with the host. The second is that disrupting the modified heptose 
synthesis is not affecting the CPS backbone structure. Therefore, the virulence phenotype 
of the mutant is related to the loss of the modified heptose as opposed to the loss of the 
capsule. Four mutants were generated containing a knockout of each of the modified 
heptose synthesis genes, wcaG::cat, mlghB::cat, mlghC::cat, and wcaG∆::cat. In this 
study, these mutants, along with the wild type as a positive control and the capsule-less 
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kpsM::kan mutant as a negative control, were used to investigate the involvement of the 
modified heptose in C. jejuni NCTC 11168 biofilm formation. 
It is important to address the physiological characteristics that could affect the 
biofilm formation of the mutants to better analyse the differences in biofilm formation 
compared to the wild type. All the heptose biosynthesis mutants lack the side branch 
modified heptose as shown previously (184). In addition, the wcaGΔ::cat does not have 
the modified heptose or any CPS modification including the MeOPN. With regards to the 
motility and agglutination of the mutants, all the heptose biosynthesis mutants are motile 
and no significance difference in the agglutination compared to the wild type(184). In 
contrast, the kpsM::kan mutant expresses non-functional flagella and has significant 
increases in agglutination forming cellular clumps (184). The growth rate of the mutants 
compared to the wild type was also analysed. The heptose biosynthesis mutants grow 
faster than the wild type, with the highest growth rate for wcaGΔ::cat mutant (184). 
In this study, the biofilm formation of C. jejuni NCTC 11168 wild type and 
mutants was tested under aerobic versus microaerobic conditions. The wild type C. jejuni 
NCTC 11168 had significantly increased biofilm formation under aerobic conditions 
(Figure 31). In contrast, the wild type biofilm were not increasing under microaerobic 
conditions (Figure 32). This was consistent with other studies that showed that the same 
strain of C. jejuni is making more biofilm under aerobic condition. The increase in 
biofilm formation protects C. jejuni cells from the atmospheric oxygen and thus allowing 
prolonged survival. 
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The wcaG::cat mutant made significantly less biofilm at both conditions, 
however, at late time points the amount of the biofilm had significantly increased. This 
means that the loss of the modified heptose in wcaG::cat mutant results in defects in 
biofilm formation. In addition, under microaerobic conditions where C. jejuni wild type 
does not need to form more biofilm over time, the wcaG::cat mutant needed to, until it 
reached the wild type levels. The same results were observed for the wcaGΔ::cat mutant. 
The early biofilm formation in wcaGΔ::cat mutant was significantly less than the wild 
type under both conditions. However, the biofilm formation had significantly increased 
over time.  The mlghC::cat mutant also had a significant reduction in biofilm formation 
compared to the wild type, but only under an aerobic conditions. The biofilm formation 
was also significantly increasing over time. However, in microaerobic conditions there 
was no significant difference between mlghC::cat mutant and the wild type. Furthermore, 
in contrast to the microaerobic wcaG::cat and wcaGΔ::cat mutants’ biofilm, the biofilm 
of mlghC::cat mutant was significantly decreased over time. On the other hand, the 
mlghB::cat mutant made significantly less biofilm than the wild type under aerobic 
conditions, but comparable biofilm to the wild type under microaerobic conditions. There 
was no change in the amount of biofilm made by mlghB::cat mutant in both conditions. 
In conclusion, under aerobic condition, the biofilm formation by wild type C. 
jejuni NCTC 11168 is increasing. The modified heptose is important for C. jejuni NCTC 
11168 biofilm formation. The biofilm formation of wcaG::cat, mlghC::cat, and 
wcaGΔ::cat mutants were significantly increasing over time just like the wild type, yet 
significantly less in the amount. This indicates that the loss of the modified heptose in 
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theses mutants could slow down the process of making the biofilm under aerobic 
condition. On the other hand, mlghB::cat mutant’s biofilm was comparable to the 
negative control and did not increase.  
Under microaerobic conditions, the biofilm formation by wild type C. jejuni 
NCTC 11168 is not increasing over time (Figure 32). This means that under favorable 
conditions, C. jejuni does not need to increase biofilm formation. However, wcaG::cat 
and wcaGΔ::cat mutants had a significant increase in the late biofilm formation. This 
suggests that the loss of the modified heptose in these mutants is stressing the bacterial 
cells and drives them to increase the formation of biofilm. The opposite is found in 
mlghB::cat mutant, where the formation of biofilm had decreased over time. Because all 
the mutants lack the modified heptose, similar phenotypes were expected. However, in a 
previous phenotypic analysis the same mutants showed variation in the results. The 
expression profile of these mutants was previously investigated and showed that deletion 
of the modified heptose genes resulted in upregulation of other CPS modification genes, 
especially in mlghC::cat and mlghB::cat mutants. This indicated that there are 
transcriptional regulatory effects that could influence the functional properties of the 
CPS. Complemented strains were generated previously for the mutants. However, they 
were unfunctional due to the presence of a very strong internal promoter that resulted in 
significant transcriptional differences within the CPS cluster. 
4.6. Future directions: 
In terms of the enzymatic analysis and the kinetics, further investigations for the 
epimerases’ and the reductases’ kinetics need to be done in order to assess the catalytic 
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activity of the mutants on GDP-manno-heptose. The GDP-manno-heptose epimerases 
and reductases active sites need to be further investigated by creating additional 
mutations by site-directed mutagenesis. Totally inactive mutants are needed to be used as 
a tool for enzyme/substrate co-crystallography. Having inactive mutant will allow 
generating a better resolution of the enzyme/substrate complex to identify the residues 
that bind directly to the substrate. A pure GDP-manno-heptose, as well as GDP-6-deoxy-
4-keto-D-lyxo-heptose substrates, will be used to soak the epimerase crystals for 
crystallography. After having the structure of the enzyme/substrate complex, the data will 
be used as basis to screen for inhibitors using chemical libraries and assess the inhibitory 
effect of the candidates if there are any. 
 
4.7. Significance and biological implications:  
In C. jejuni, the major cause of gastroenteritis in humans, the putative heptose 
epimerases and reductases of 81-167 and NCTC 11168 strains can be potential 
antimicrobial targets due to their involvement in C. jejuni virulence, such as biofilm 
formation. This project is the first to identify the structure and the potential role of the 
functional residues in the active site of theses enzymes. The identification of specific 
structural and functional characteristics is fundamental for designing specific inhibitors.  
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Appendix 1: Subcloning primers 
Primer 
name 
Sequence ( 5’ – 3’) 
MlghB P2 AGGGTCCATGGCAATAGAATTTGATATA 
MlghB P3 GCGTCGGATCCTTATCCTTTATTTTTAGTTGCAA 
DdahB P2 GCTGGATCCTTATCCTTTATTTTTAGTTGCT 
DdahB P3 CTCACATGTCCATGGCAATAGAATTTAATATAC 
 
 Restriction sites are in bold and underlined 
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Appendix 2: SDM primers 
Gene Mutation Primers Sequence ( 5’ – 3’) 
Epimerases 
DdahB 
Asn121Ser* 
F:GTGCCAGCAGGTTTTGGAAGCGCTCATTATGTT
ACT AGTG 
R:CACTAGTAACATAATGAGCGCTTCCAAAACCT
GCTG GCAC 
His67Ala 
F:CAATGTTATTCGCGGTATCGCTGGTGATGTAAA
AA CTTATAAGCTTG 
R:CAAGCTTATAAGTTTTTACATCACCAGCGATAC
CG CGAATAACATTG 
His67Asn 
F:CAATGTTATTCGCGGTATCAATGGTGATGTAAA
AAC TTATAAGCTTG 
R:CAAGCTTATAAGTTTTTACATCACCATTGATAC
CGC GAATAACATTG 
Lys74Ala 
F:CCATGGCGATGTAAAAACTTATGCGCTTGCAAC
TTG TGTTTATGG 
R:CATAAACACAAGTTGCAAGCGCATAAGTTTTT
ACAT CGCCATGG 
MlghB 
Asn121Ser* 
F:ATTACCACCAAATATGGGAAGCTCTCATTATGT
GAG TTCAAAG 
R:CTTTGAACTCACATAATGAGAGCTTCCCATATT
TGGT GGTAAT 
His67Ala* 
F:CCCATTTTAATGTTTTACGTGGAATAGCCGGAG
ATGT GAAAACTTAC 
R:GTAAGTTTTCACATCTCCGGCTATTCCACGTAA
AACA TTAAAATGGG 
His67Asn 
F:CCCATTTTAATGTTTTACGTGGAATAAACGGAG
ATG TGAAAACTTAC 
R:GTAAGTTTTCACATCTCCGTTTATTCCACGTAA
AACA TTAAAATGGG 
Tyr134Phe* 
F:CAAAGGAAGCAGTGTATTATTTTAAACTTGCTT
ATGA GGGG 
R:CCCCTCATAAGCAAGTTTAAAATAATACACTGC
TTCC TTTG 
Tyr132Phe** 
F:GAGTTCAAAGGAAGCAGTGTTTTATTATAAACT
TGCTTATG 
R: CATAAGCAAGTTTATAATAAAACACTGCTTCC 
TTTGAACTC 
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Lys74Ala 
F:CACGGAGATGTGAAAACTTACGCACTTGTAACT
TGTG TCTATGGAG 
R:CTCCATAGACACAAGTTACAAGTGCGTAAGTTT
TCAC ATCTCCGTG 
Reductases 
DdahC 
His180Arg* 
F:GACAAATTTGATCTTGAAAAATCTCGTGTATTG
CCTGG AATTTTA AGAAA AATG 
R:CATTTTTCTTAAAATTCCAGGCAATACACGAGA
TTTTT CAAGATCAAA TTTGTC 
Thr110Tyr 
F:GCTACTTTTCATAGCTTCAACTTACGTTTATCCT
AAAA ATGCAACATTG 
R:CAATGTTGCATTTTTAGGATAAACGTAAGTTGA
AGCT ATGAAAAGTA GC 
His180Arg/ 
 Thr110Tyr* 
Both His180Arg and Thr110Tyr 
Thr110Cys* 
F:CTACTTTTTTCATAGCTTCAACTTGCGTTTAT
CCTAA AAATGCAAC ATTG 
R:CAATGTTGCATTTTTAGGATAAACGCAAGTTGA
AGC TATGAAAA AAGTAG 
MlghC Cys68Ala* 
F:GACTGCAGTCTTACCTGCTGGTGCTGCAAATGT
CG 
R:CGACATTTGCAGCACCAGCAGGTAAGACTGCA
GTC 
 
*SDM done by Michael Roubakha, 2013 
** SDM done by Chelsea Kubinec, 2015 
F and R indicate forward and reverse primer respectively.   
Mutated residues codons are in bold, and the mutated nucleotides are underlined. 
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Appendix 3: Antibodies used for Western blot 
Primary antibody 
and dilution* 
Epitope 
detected 
Secondary 
antibody 
Wavelength 
detected (nm) 
Monoclonal anti-His  
(mouse), 1:5000 
His6 Tag 
Anti-mouse ( goat) 
1:5000 
700 
Monoclonal anti-
GST (rabbit), 1:3000 
GST Tag 
Anti-rabbit ( goat) 
1:2000 
800 
 
* Dilution was made in 1 PBS buffer and 0.05 % sodium azide. 
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Appendix 4: Integration data of the CE electropherograms for the epimerases 
activity on GDP-manno-heptose: 
The table shows the means of three independent experiments (Figure 21-A2,B2). The 
products are represented by their order of appearance in the CE electropherograms. The 
data represent the area of each peak in percentage to the total area of the sugar 
nucleotides. The impurity and NADP+ peaks were excluded from the integration. 
Enzyme P4γ P1 P4β P4α 
(Percentage %) 
DdahB H67N 0.0 88.8 0.0 11.2 
DdahB H67A 0.0 90.0 0.0 10.0 
DdahB N121S 0.0 70.6 0.0 29.4 
DdahB WT 0.0 63.7 0.0 36.3 
DdahA 0.0 100.0 0.0 0.0 
 
(Percentage %) 
MlghB Y134F 13.0 74.4 6.4 8.3 
MlghB H67N 0.0 93.1 0.0 6.9 
MlghB H67A 0.0 89.2 0.0 10.8 
MlghB N121S 25.0 35.7 29.0 20.0 
MlghB WT 22.2 28.8 25.6 31.9 
DdahA 0.0 100.0 0.0 0.0 
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Appendix 5: Integration data of the CE electropherograms for the epimerases 
activity on GDP-mannose: 
The table shows the means of two independent experiments (Figure 23-B2). The products 
are represented by their order of appearance in the CE electropherograms. The data 
represent the area of each peak in percentage to the total area of the sugar nucleotides. 
The GDP-mannose peak was excluded from the integration. 
Enzyme P4’ P1’ 
 
(Percentage %) 
DdahB H67N 0.0 100 
DdahB H67A 0.0 100 
DdahB N121S 0.0 100 
DdahB WT 6.5 93.5 
 
(Percentage %) 
MlghB Y134F 10.1 89.9 
MlghB H67N 0.0 100.0 
MlghB H67A 0.0 100.0 
MlghB N121S 43.0 57.0 
MlghB WT 42.2 57.9 
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Appendix 6: Integration data for CE electropherograms shown in Figure 25 
The traces and are represented in their order in the figure. The peaks are represented by 
their order of appearance in the CE electropherograms. For panel A, the dada represent 
the area of each peak in percentage to the total area of the sugar nucleotides. P4β peak 
was excluded from the integration because of the poor resolution from NADP+. The 
impurity peak was also excluded. For panel B, the data for the substrates and the 
products peaks areas are represented in ratio to the impurity peak area (annotated as *), 
assuming that all traces has the same amount of the impurity. The peak of NADP+ and the 
co-migrated P4β were included in the integration. This was done in order to evaluate the 
changes in the substrate specificity of the mutants. MlghB reaction trace could not be 
used as a control. Instead, the inactive DdahC H180R/T110Y mutant was used as a 
virtual control.  
Trace Enzyme P5γ P4γ P1 P5α P4α   
Panel A (Percentage %)   
g MlghC C68A 56.7 9.3 17.5 0.0 16.4   
f MlghC WT 63.4 4.9 13.2 0.0 18.4   
e DdahC H180R/T110Y 0.0 25.9 34.5 0.0 39.6   
d DdahC H180R 0.0 21.7 24.2 35.4 18.7   
c DdahC T110C 0.0 17.2 20.1 46.0 16.7   
b DdahC WT 0.0 23.2 24.2 31.1 21.5   
Trace Enzyme P5γ P4γ P1 P5α NADP
+ 
P4β P4α * 
Panel B   
(Ratio to *) 
g MlghC C68A 0.45 0.95 1.61 0.00 2.28 0.38 1.00 
f MlghC WT 0.87 0.62 1.50 0.00 2.61 0.41 1.00 
e DdahC H180R/T110Y 0.00 1.22 1.48 0.00 0.97 0.44 1.00 
d DdahC H180R 0.00 1.21 1.46 0.08 1.44 0.34 1.00 
c DdahC T110C 0.00 1.25 1.38 0.33 1.78 0.26 1.00 
b DdahC WT 0.00 1.37 1.69 0.16 1.12 0.36 1.00 
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